 
 
Official Title:  A Phase IB -II Study Of High -Dose Post -Transplant Cyclophosphamide, 
Abatacept, and Short -Duration Tacrolimus for the Prevention of Graft -
Versus -Host Disease (GvHD) Following Haploidentical Hematopoietic 
Stem Cell Transplantation (HSCT)   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  20-00136  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • July 5, 2022  
 
 
Study number: s20- 00136   Page i 
Version: 5. 1 dtd 2022 Jun 07  
   
 
A PHASE IB -II STUDY OF HIGH- DOSE POST -TRANSPLANT 
CYCLOPHOSPHAMIDE , ABATACEPT, AND SHORT -DURATION TACROLIMUS FOR 
THE PREVENTION OF GR AFT-VERSUS- HOST DISE ASE (GVHD) FOLLOWING 
HAPLOIDENTICAL HEMATOPOIETIC STEM C ELL TRANSPLANTATION (HSCT)  
 
Initial version:  [May 2020] 
Amended:  [February 2020]  
Amended v3: April 2021  
Amended v4: June 2021 
Amended v5: Dec 2021 
Administrative Amendment v5.1: 2022 Jun 07  
  
Principal Investigator:  
 A Samer Al -Homsi MD, MBA  
Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
Samer.Al -Homsi@nyulangone.org  
Biostatistician:  Judith D. Goldberg, ScD  
Pharmacist:  Frank Cirrone, PharmD  
NYULH Study Number:  s20-00136  
Funding Sponsor:  Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
IND Number:  IND 149936  
Regulatory Sponsor:  Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
NYULH Medical Monitor:  David L. Green, MD  
Study Product:  Cyclophosphamide, abatacept, and tacrolimus  
Study Product Provider:  Cyclophosphamide,  abatacept, and tacrolimus are covered as 
standard of care.  
ClinicalTrials.gov 
Number : [STUDY_ID_REMOVED]  
Study number: s20- 00136   Page ii 
Version: 5. 1 dtd 2022 Jun 07  
   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection 
of Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other 
applicable US government research regulations, and institutional research policies and procedures. The Inte rnational Conference on Harmonization (“ICH”) Guideline for Good Clinical 
Practice (“GCP”) (sometimes referred to as “ICH -GCP” or “E6”) will be applied only to the extent 
that it is compatible with FDA and DHHS regulations. The Principal Investigator will assure that 
no deviation from, or changes to the protocol will take place without prior agreement from the 
Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
Study number: s20- 00136   Page iii 
Version: 5. 1 dtd 2022 Jun 07  
   
PROTOCOL APPROVAL SIGNATURES  
 
Protocol Title:  A PHASE IB -II STUDY OF HIGH- DOSE  POST -TRANSPLANT 
CYCLOPHOSPHAMIDE, AB ATACEPT, AND SHORT -DURATION TACROLIMUS FOR THE 
PREVENTION OF GRAFT -VERSUS- HOST DISEASE (GVHD) FOLLOWING 
HAPLOIDENTICAL HEMAT OPOIETIC STEM CELL TRANSPLANTATION  (HSCT)  
 
 
Protocol Number: s20 -00136 
 This study will be conducted in compliance with the clinical study protocol (and amendments), International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines for current Good Clinical Practice, and applicable 
regulatory requirements.  
    
 
_______________________________________ Signature  
 
 
_______________________________________ Date  
  
Study number: s20- 00136   Page iv 
Version: 5. 1 dtd 2022 Jun 07  
   
 
TABLE OF CONTENTS   
 
STATEMENT OF COMPLIANCE  ................................................................................................................. II 
LIST OF ABBREVIATION S........................................................................................................................ VII 
PROTOCOL SUMMARY  .............................................................................................................................. 1  
SCHEMATIC OF STUDY DESIGN  ............................................................................................................... 3  
1 KEY ROLES  ......................................................................................................................................... 4  
2 BACKGROUND RATIONALE  ............................................................................................................. 5  
2.1 POTENTIAL RISKS AND BENEFITS  .................................................................................................... 7  
2.1.1  Known Potential Risks  ............................................................................................................. 7  
2.1.2  Other Risks of Study Part icipation ........................................................................................... 8  
2.1.3  Known Potential Benefits  ........................................................................................................ 8  
3 OBJECTIVES AND PURPOSE  ........................................................................................................... 9  
3.1 STUDY HYPOTHESIS  ....................................................................................................................... 9  
3.2 STUDY OVERVIEW  .......................................................................................................................... 9 
3.3 OBJECTIVES  .................................................................................................................................. 9  
3.3.1  Primary Objectives  .................................................................................................................. 9 
3.3.2  Secondary Objectives  ............................................................................................................. 9 
3.4 STUDY ENDPOINTS ......................................................................................................................... 9 
3.4.1  Primary Study Endpoints  ......................................................................................................... 9  
3.4.2  Secondary Study Endpoints  .................................................................................................... 9  
3.5 DEFINITIONS  ................................................................................................................................ 10 
4 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................. 10 
4.1 INCLUSION CRITERIA  .................................................................................................................... 10 
4.2 EXCLUSION CRITERIA  ................................................................................................................... 11 
4.3 INCLUSION OF WOMEN , MINORITIE S, AND VULNERABLE POPULATIONS  ............................................ 11 
4.4 STRATEGIES FOR RECRUITMENT AND RETENTION  .......................................................................... 11 
4.5 REGISTRATION PROCEDURES  ....................................................................................................... 12 
4.6 DURATION OF STUDY PARTICIP ATION  ............................................................................................ 13 
4.7 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................................................................ 13 
4.8 PARTICIP ANT WITHDRAWAL OR TERMINATION  ................................................................................ 13 
4.8.1  Reasons for Withdrawal or Terminat ion ................................................................................ 13 
4.8.2  Handling of Participant Withdrawals or Termination  ............................................................. 13 
4.9 PREMATURE TERMI NATION OR SUSPENSION OF STUDY  .................................................................. 13 
4.10  STOPPING  RULES  ......................................................................................................................... 14 
5 STUDY AGENTS  ............................................................................................................................... 15 
5.1 CYTOXAN ® (CYCLOPHOSPHAMIDE ) ............................................................................................... 15 
5.2 PROGRAF ® (TACROLIMUS ) ........................................................................................................... 16 
5.3 ORENCIA ® (ABATACEPT ) .............................................................................................................. 19 
5.4 STUDY AGENT ACCOUNTABILITY PROCEDURES  ............................................................................. 22 
5.5 PRODUCT COMPLAINTS  ................................................................................................................ 22 
6 REQUIRED STUDY ACTIVITIES (APPENDIX  A) ............................................................................. 22 
6.1 RECIPIENT PRE-TRANSPLANT WORK-UP AND ELIGIBILITY FOR TRANSPLANT  ................................... 22  
6.2 DONOR WORK-UP ....................................................................................................................... 22  
6.3 PRE-TRANSPLANT  ........................................................................................................................ 23 
6.4 POST-TRANSPLANT  ...................................................................................................................... 23 
7 TREATM ENT PLAN ........................................................................................................................... 23 
Study number: s20- 00136   Page v 
Version: 5. 1 dtd 2022 Jun 07  
   
7.1 CONDITIONING REGIMEN (STUDY SCHEMA ) ................................................................................... 23 
7.1.1  Non-myeloablative conditioning ............................................................................................ 23 
7.1.2  Reduced- intensity conditioning  ............................................................................................. 23 
7.1.3  TBI-based myeloablative conditioning  .................................................................................. 23  
7.1.4  Non TBI -based myeloablative conditioning  ........................................................................... 23  
7.2 GRAFT INFUSION  .......................................................................................................................... 24 
7.3 GVHD PROPHYLAXIS  ................................................................................................................... 24 
7.4 DRUG PREPARATION  .................................................................................................................... 24 
7.5 SUPPORTIVE CARE ...................................................................................................................... 24 
7.6 MANAGEM ENT OF ACUTE AND CHRONIC GVHD ............................................................................. 24  
7.7 FOLLOW -UP AND DATA COLLECTION  ............................................................................................. 24  
7.8 ANCILLARY THERAPY .................................................................................................................... 24 
7.9 DOSE ADJUSTMENTS  .................................................................................................................... 24  
8 ASSESSMENT OF SAFETY  ............................................................................................................. 25 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 25 
8.2 ADVERSE EVENTS (AE) ................................................................................................................ 25 
8.2.1  Definitions  of Adverse Events  ............................................................................................... 25 
8.2.2  Reporting an Adverse Event  ................................................................................................. 25  
8.3 SERIOUS ADVERSE EVENTS (SAE)  ............................................................................................... 26 
8.3.1  Definit ion of Serious Adverse Events  .................................................................................... 26 
8.3.2  Reporting a Serious Adverse Event  ...................................................................................... 26 
8.4 OVERDOSE  .................................................................................................................................. 28  
8.5 OTHER SAFETY CONSIDERAT IONS ................................................................................................. 28  
8.6 DEFINITION O F UNANTICIPATED PROBLEMS (UP) ........................................................................... 28  
8.7 CLASS IFICATION OF AN ADVERSE EVENT  ....................................................................................... 29 
8.8 NON-SERIOUS ADVERSE EVENT COLLECTION REPORTING  ............................................................. 30 
8.9 EXPECTEDNESS  ........................................................................................................................... 30 
8.10  REPORTING OF PREGNANCY  ......................................................................................................... 30 
8.11  REPORTING PROCEDURES - NOTIFYING THE IRB ........................................................................... 30  
8.12  REPORTING PROCESS  .................................................................................................................. 31  
8.13  OTHER REPORTABLE EVENTS  ....................................................................................................... 32 
8.14  STUDY HALTING RULES ................................................................................................................ 32 
8.15  SAFETY OVERSIGHT  ..................................................................................................................... 33 
9 CLINICAL MONITORING  .................................................................................................................. 33 
9.1 DATA MONITORING COMMITTEE  .................................................................................................... 33 
10 STATISTICAL CONSIDER ATIONS  .................................................................................................. 34 
10.1  SAMPLE SIZE  ................................................................................................................................ 34 
10.2  STATISTICAL ANALYSIS  ................................................................................................................. 34 
10.3  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT (S) ...................................................................... 34  
10.4  ANALYSIS OF THE SECONDARY ENDPOINT (S) ................................................................................. 35 
10.5  MISSING DATA ............................................................................................................................. 35  
10.6  SAFETY ANALYSES  ....................................................................................................................... 35  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/ DOCUMENTS  ................................. 36 
12 QUALITY ASSURANCE AND QUALITY  CONTROL  ....................................................................... 37 
13 ADMINISTRATIVE REQUI REMENTS  ............................................................................................... 38 
13.1  GOOD CLINICAL PRACTICE  ........................................................................................................... 38 
13.1.1  Ethical Considerations  ........................................................................................................... 38 
13.2  PATIENT INFORMATION AND INFORMED CONSENT  .......................................................................... 38 
13.2.1  Informed Consent  .................................................................................................................. 39 
13.2.2  Documentation of Consent  .................................................................................................... 39 
13.2.3  Posting of Clinical Trial Consent  ........................................................................................... 39 
Study number: s20- 00136   Page vi 
Version: 5. 1 dtd 2022 Jun 07  
   
13.2.4  Participant and Data Confidentiality  ...................................................................................... 39 
14 DATA HANDLING AND RECORD KEEPING  ................................................................................... 40  
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 40  
14.2  STUDY RECORDS RETENTION  ....................................................................................................... 41 
14.3  PROTOCOL DEVIATIONS  ............................................................................................................... 41 
14.4  PUBLICATION AND DATA SHARING POLICY  ..................................................................................... 41  
15 STUDY FINANCES  ............................................................................................................................ 42 
15.1  FUNDING SOURCE  ........................................................................................................................ 42 
15.2  COSTS TO THE PARTICIPANT  ......................................................................................................... 42 
15.3  PARTICIPA NT REIMBURSEMENTS OR PAYMENTS  ............................................................................ 42 
16 CONFLICT OF INTEREST  POLICY  .................................................................................................. 42  
17 REFERENCES  ................................................................................................................................... 43  
18 APPENDICES  .................................................................................................................................... 44 
18.1  APPENDIX  A: REQUIRED STUDY ACTIVITIES  ................................................................................... 45  
18.2  APPENDIX B: ACUTE GRAFT -VERSUS -HOST DISEASE ASSESSMENT (AGVHD)  ............................... 46  
18.3  APPENDIX C: CHRONIC GRAFT -VERSUS -HOST DISEASE ASSESSMENT (CGVHD)  ........................... 47  
18.4  APPENDIX D: NEW YORK HEART ASSOCIATION (NYHA)  CLASSIFICATION OF CARDIAC DISEASE  ...... 48  
  
Study number: s20- 00136   Page vii 
Version: 5. 1 dtd 2022 Jun 07  
   
List of Abbreviations  
 
ADR  Adverse drug reaction  
AE Adverse Event or Adverse Experience 
ALP Alkaline phosphatase  
ALT Alanine Aminotransferase 
ANC  Absolute Neutrophil Count  
AST Aspartate Aminotransferase 
ATG Anti-thymocyte globulin 
BP Blood Pressure  
BUN  Blood Urea Nitrogen  
CBC  Complete Blood Count  
Cl Confidence Interval  
CNI Calcineurin inhibitors  
CrCl Creatinine Clearance  
CFR Code of Federal Regulations  
CRF Case Report Form  
CSOC Clinical Study Oversight Committee  
CTO  Clinical Trials Office  
DC Dendritic cell 
DSMC  Data Safety Monitoring Committee  
ECI 
ECRF  
EMR  Event of Clinical Interest  
Electronic Case Report Form  
Electronic Medical Record  
GRFS  GvHD and r elapse -free survival  
GvHD Graft -versus -Host Disease  
GvT Graft -versus -tumor  
HSCT  Hematopoietic stem cell transplantation  
LFTs  Liver function tests  
LPS Lipopolysaccharide  
MMF  Mycophenolate mofetil  
MTX  Methotrexate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cells  
PI Proteasome inhibitor s 
PTC Post-Transplant cyclophosphamide  
rATG  Rabbit anti-thymocyte globulin  
Study number: s20- 00136   Page viii 
Version: 5. 1 dtd 2022 Jun 07  
   
RR Relapse rate  
TRM  Treatment -related mortality  
UP Unanticipated Problems  
Study number: s20- 00136   Page 1 
Version: 5.1 dtd 2022 Jun 07 
 
1 Protocol Summary  
Title A PHASE IB -II STUDY OF HIGH -DOSE POST -TRANSPLANT CYCL OPHOSPHAMIDE, 
ABATACEPT, AND SHORT -DURATION TACROLIMUS FOR THE P REVENTION OF 
GRAFT -VERSUS- HOST DI SEASE (GVHD) FOLLOWI NG HAPLOIDENTICAL 
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)  
Short Title Cyclophosphamide, abatacept, and tacrolimus  for GvHD p revention  
Brief Summary  This is a single arm , open label , optimal 2 -stage Simon design phase Ib -II clinical trial.  Adult 
patients with hematological malignancies undergoing allogeneic HSCT from first- or second-
degree haploidentical donor are eligible for the study if they meet the standard criteria 
defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, 
and do not satisfy any exclusion criteria. Patients will receive non- myeloablative, reduced-
intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic 
stem cells.  Patients will receive cyclophosphamide, abatacept, and short -duration 
tacrolimus for GvHD prophylaxis .  
Phase Phase Ib-II 
Objectives  Primary Objective:  
• Estimate  the incidence of grade II -IV acute  GvHD  in patient s receiving 
cyclophosphamide,  abatacept, and tacrolimus  as GvHD prophylaxis . 
Secondary Objectives: 
• Estimate the incidence of chronic GvHD in patients receiving cyclophosphamide 
abatacept, and tacrolimus as GvHD prophylaxis  
• Estimate  the incidence of the following: primary graft failure, poor graft function, and 
secondary graft failure, treatment- related mortality (TRM), relapse rate (RR), and 
relapse- free survival (GRFS), and overall survival (OS).  
• Assess immune reconstitution by quantifying CD3+, CD4+, CD8+, and CD19+ in  
comparison to established reference data  
Methodology  Interventional, non -randomized open label , 2- stage optimal Simon design with interim futility 
analysis . 
Endpoint  Primary: Grade II -IV acute GvHD by day +120.  
Secondary: Chronic GvHD, TRM, RR, GRFS, and OS.  
Study Duration  Study will complete 2  years after the final participant’s date of transplant. Anticipate 4 years 
to complete enrollment and thus a 6-year total duration.  
Participant 
Duration  Up to 2  years  
Enrollment Period Up to 4 years 
Duration of IP 
administration  Up to 4  week s 
Number of 
participants  46 participants enrolled 
Study number: s20- 00136   Page 2 
Version: 5.1 dtd 2022 Jun 07 
 
2 Description of 
Study Procedure  Cyclophosphamide 50 mg/kg IV over 1 hour on Day +3 and +4  
Abatacept 10 mg/kg IV on day s +5, +14, and +28  
Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral 
when tolerated, adjusted to maintain a drug level between 5- 12ng/mL. Treatment is 
discontinued on day +60 after a 4 week -taper  
Key Procedures  
 Examin ations to include toxicity and GvHD assessments and blood draws to assess immune 
reconstitution.  
Statistical Analysis  Sample size: The primary outcome variable for this study is the incidence of grades II -IV 
acute GvHD.  We assume that the rate of grade II-IV acute GvHD, with the standard of care 
is 50%, as reported in the literature and 30% in the experimental group. Based on a 2 -stage 
optimal Simon design, we can detect a reduction in the grade II –IV acute GvHD incidence 
to 30% for high- dose post -transplant cyclophosphamide abatacept, and tacrolimus , with 
alpha = 0.05 and power of 82% at the conclusion of the 2 -stage design with 46 patients. The 
trial would stop for futility at the end of the first stage if 9 or more patients have grade II -IV 
acute GVHD, of the 22 patients enrolled. Otherwise, the trial will continue to the second 
stage with the total 46 patients enrolled. If the total number of patients with grade II -IV acute 
GVHD is 19 or greater at the end of stage II, the regimen will not be considered for further study. The rate of grade II -IV acute GVHD will be estimated at the end of the trial with exact 
95% Clopper Pearson confidence intervals. If the observed rate is 30%, this exact 
confidence interval with 46 patients, the corresponding confidence interval will be 17.4% to 45.3%. Calculations from PASS 2019, NCSS, J. Hintze, Kaysville, Ut.  
 
The primary analyses will include all patients who are transplanted and receive treatment. All endpoints will be evaluated using cumulative incidence functions; exact 95% confidence 
intervals will be provided for the day +120 incidence for acute GvHD. Secondary analyses 
will estimate  the occurrence of chronic GvHD, primary graft fa
ilure, poor graft function, 
secondary graft failure, TRM, RR, GRFS, and OS.  
 
  
Study number: s20- 00136   Page 3 
Version: 5.1 dtd 2022 Jun 07 
 
3 Schematic of Study Design  
 
 
 
  

Study number: s20- 00136   Page 4 
Version: 5.1 dtd 2022 Jun 07 
 
4 1. KEY ROLES  
 
A Samer Al -Homsi MD,  MBA - Principal Investigator  
Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
Samer.Al- Homsi@nyulangone.org  
  Frank Cirrone,  PharmD - Pharmacist  
545 First Avenue New York, NY 10016  
Frank.Cirrone@nyulangone.org  
 
Judith D Goldberg, ScD -co-Investigator and B iostatistics  
Division of Biostatistics, Dept. of Population Health and  
Perlmutter Cancer Center  
NYU Langone Health  
190 Madison Ave, 4th floor, 451  
New York, NY 10016  
JD.Goldberg@nyulangone.org  
 
Kelli Cole, FNP -BC-Study Coordinator  
Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
Kelli.Cole@nyulangone.org  
 
Kelsey Stocker, RN - Research Nurse  
Perlmutter Cancer Center  
240 East 38th Street  
New York, NY 10016  
Kelsey.Stocker@nyulangone.org  
 
  
Study number: s20- 00136   Page 5 
Version: 5.1 dtd 2022 Jun 07 
 
5 2. BACKGROUND AND RATIONALE  
 
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for 
a variety of benign and malignant hematological  conditions  [1]. According to the Center for 
International Bone Marrow Transplant Research (CIBMT R), more than 13,000 allogeneic HSCTs 
are performed annually in the US  alone ( http://www.cibmtr.org ).  
 
The stem cell source for allogeneic HSCT has historically been from an HLA -matched related 
donor (MRD) or matched unrelated donor  (MUD) . However, such donor can be identified or 
mobilized in less than 50% of cases  [2]. In particular, the availability of a MUD can be lower for 
members of certain ethnic groups who are underrepresented in the donor registries, including 
African Americans, Hispanics, and Asians  [2]. In contrast, an HLA- haploidentical first - or second -
degree relative can be identified and mobilized rapidly for nearly any patient  [3]. At Johns Hopkins 
University, More than 95% of patients were found to have at least 1 HLA -haploidentical first -
degree donor with an average number of donors per patient of 2.7 [3].  
 The Outcomes of HLA -haploidentical transplantation have improved substantially over the past 
decade [4]. Multiple studies have now demonstrated that the outcomes of HLA -haploidentical 
transplantation and MUD are comparable (Table 1)  [4]. Furthermore, the Blood and M arrow 
Transplant Clinical Trial Network (BMT CTN) has completed a two parallel phase II studies of  
either HLA- haploidentical related donor bone marrow transplants or double -unrelated donor cord 
blood transplantation in patients with hematolo gical malignancies. The  outcomes of the two 
cohorts were comparable. The  100-day incidence of grade II -IV acute GvHD was 32% in HLA -
haploidentical transplantation and 40% in cord blood transplantation. The 1- year cumulative 
incidence of treatment -related m ortality (TRM)  and relapse rate (RR) were 7% and 45% for HLA -
haploidentical transplantation and 24% and 31% for cord blood transplantation. The 1 -year 
probabi lity of overall survival (OS)  was 62% and 54% , respectively  [5]. Nowadays, HLA-
haploidentical transplantation represents an acceptable alternative in patients who lack a MRD  
[4]. According to the CIBMTR, the use of MUD and cord blood transplantation has declined in 
recent years in favor of HLA- haploidentical donor transplantation (Figure 1).  
 
 
Table 1  

Study number: s20- 00136   Page 6 
Version: 5.1 dtd 2022 Jun 07 
 
6 The major drawback of HLA -haploidentical transplantation is the intense bidirectional 
alloreactivity  [2]. The early studies of HLA -haploidentical transplantation have demonstrated the 
fundamental challenge inherent in  crossing HLA barriers. Without T -cell depletion, the incidence 
of GvHD is high with TRM in excess of 50%. On the other hand, if T- cells are depleted from the 
graft, there is an unacceptable risk of graft failure, opportunistic infections and disease relapse. 
To overcome these challenges, selective T- cell depletion and  add on strategies are being 
explored [6-8]. Alternatively, post -transplantation cyclophosphamide (PTC) can circumvent the 
need to graft manipulation and has emerged as an alternative approach to graft manipulation [9].   
 
Figure 1  
 
PTC for GvHD prevention:  
Since introduced by the Johns Hopkins University group, PTC has been extensively studied in 
HLA-haploidentical transplant ation,  following non-myeloablative and myeloablative conditioning 
regimens. Contrary to calcineurin inhibitors  (CNI), methotrexate (MTX), and mycophenolate 
mofetil (MMF) , PTC selectively destroys rapidly proliferating host -reactive T cells, fosters 
regulatory T cells (T reg) expansion and induces long -lasting tolerance by deleting intra- thymic 
alloreactive T cells  [9]. Because of its selective activity, targeting proliferating rather than resting 
T cells, PTC has been claimed to nurture rapid immune reconstitution and preserve GvT effect  
[10]. Several studies, using non -myeloablative and myeloablative conditioning regimens and 
HLA-haploidentical related- donor transplantation have now validated this approach with PTC, 
tacrolimus and MMF used as  GvHD prevention. Although the original studies focused on the use 
of bone marrow as the source of grafts, recent studies using peripheral blood grafts have reported comparable outcomes [11 -16].  
 
Abatacept for GvHD prevention:  
Abatacept is a recombinant soluble fusion protein composed of the extracellular domain of 
cytotoxic T -lymphocyte associated antigen -4 (CTLA -4) fused to the Fc region of IgG1. Abatacept 
blocks CD28 -CD80I86 axis T -cell co -stimulation thus preventing T -cell activation  [17]. Abatacept 
is FDA approved for adult rheumatoid arthritis, juveni le idiopathic  arthritis and adult psoriatic 
arthritis.  
 A phase I feasibility  study using a short -course of abatacept in unrelated- donor allogeneic HSCT 
suggested the safety and potential efficacy of abatacept in the prevention of severe acute GvHD. 

Study number: s20- 00136   Page 7 
Version: 5.1 dtd 2022 Jun 07 
 
7 In a recent larger study  the role of abatacept in the prevention of aGvHD was examined in two 
cohorts of patients. The first cohort  received a one locus -HLA mismatched unrelated -donor 
transplant. Patients received a combination of tacrolimus and methotrexate and in addition , 
abatacept , given at 10mg/kg on day - 1, +5, +14, and +28. The cohort was compared to a registry -
matched cohort receiving tacrolimus  and methotrexate with or without rabbit anti -thymocyte 
globulin (rATG). The outcomes were improved in the group that received abatacept with a 
reduced rate of grade III -IV acute GvHD (3% v 32%, p=0.0003 in comparison to the group that 
did not receive rATG  and 3% v 22%, p=0.0054 in comparison to the group that received rATG). 
GvHD and relapse- free survival was also improved, as was disease- free survival. The rates of 
relapse were 8%, 21%, and 18% respectively (p=0.099 and 0.23). The second cohort included 
140 patients receiving HLA -matched donor transplant,  randomized in a double- blinded fashion to 
receive tacrolimus and methotrexate with either placebo or abatacept. Grade III -IV acute GvHD 
was reduced in the group that received abatacept in comparison to placebo (7% v 15%, p=0.66). 
GRFS was also reduced (89% v 77%, p=0.05). There was no difference in TRM or relapse rate 
between the two groups. The authors concluded that a short -course of abatacept was safe and 
effective in the prevention of aGv HD without inc reasing relapse- rate [18]. In a smaller study, 
abatacept was combined with PTC and tacrolimus in patients receiving MRD or MUD transplants. 
Abatacept was given at 10mg/kg on day +5, +14, and +28. The treatment was deemed safe and 
no patients developed acut e GvHD  [19].  
 Abatacept has now been granted a breakthrough therapy designation for the prevention of moderate to severe acute GvHD.  
 
Duration of tacrolimus for GvHD prevention:  
Tacrolimus targets T -cells indiscriminately. Its use following allogeneic H SCT is therefore 
associated with delayed immune reconstitution and impairment of graft-versus -tumor effect. 
Tacrolimus is  also burdensome to use due to narrow therapeutic index that requires close drug 
level monitoring with multiple drug interactions and side effects including renal impairment and electrolyte wasting.  Lastly, prolonged administration of tacrolimus delays the  introduction of 
immune maneuvers and small molecules aimed to reduce the risk of relapse following allogeneic 
HSCT.  
There is paucity of prospective data on the optimal duration of CNI following allogeneic HSCT. 
The J ohns Hopkins group recently reported the results of a single arm trial. Tacrolimus was pre-
specified to stop on day +60, +90, or +120 without pre -taper following HLA-haploid entical 
transplant with bone marrow grafts and PTC, tac rolimus and MMF for GvHD prevention. Safety 
stopping rules were not met. The incidence of grade II -IV and grades III -IV acute GvHD were 
<40% and <8% in both day +60 and day +90 arms. The GRFS rate was higher in the +60 arm. 
The authors concluded that stopping tacrolimus at day +60 was feasible and safe [20 ].  
 
Based on the above, we propose a phase Ib-II study using PTC,  abatacept  and short -duration 
tacrolimus for GvHD prevention following HLA -haploidentical allogeneic HSCT in patient s with 
hematological malignancies.  
 
2.1. Potential Risks & Benefits  
2.1.1.  Known Potential Risks  
 
Study number: s20- 00136   Page 8 
Version: 5.1 dtd 2022 Jun 07 
 
8 2.1.1.1.  Cyclophosphamide  
The most common side effects of c yclophosphamide ( Cytoxan® ): 
• Hematopoietic system: Neutropenia occurs in patients treated with 
cyclophosphamide. The degree of neutropenia is particularly important 
because it correlates with a reduction in resistance to infections. Fever without 
documented infection has been reported in neutropenic patients.  
 
• Gastrointestinal system: Nausea and vomiting occur with cyclophosphamide 
therapy. Anorexia and, less frequently, abdominal discomfort or pain and 
diarrhea may occur. There are isolated reports of hemorrhagic colitis, oral 
mucosal ulceration and jaundice occurring during therapy.  
 
• Skin and its structures: Alopecia occurs in patients treated with cyclophosphamide. Skin rash occurs occasionally in patients  receiving the 
drug. Pigmentation of the skin and changes in nails can occur.   
 
Full prescribing information available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s1
12lbl.pdf  
 
2.1.1.2.  Abatacept  
The most common side effects of  abatacept (Orencia®) :  
The most common adverse reactions events (≥ 10%) are headache, upper  respiratory 
tract infection, nasopharyngitis, and nausea . 
 
2.1.1.3.  Tacrolimus  
The most common side effects of tacrolimus (Prograf®):  
The most common adverse reactions (≥ 15%) are  abnormal renal function, 
hypertension, diabetes mellitus, fever, CMV infection, tremor, hyperglycemia, 
leukopenia, infection, anemia, bronchitis, pericardial effusion, urinary tract infection, constipation, diarrhea, headache, abdominal pain, insomnia, paresthesia, peripheral edema, nausea, hyperkalemia, hypomagnesemia, and hyperlipid emia.  
 
2.1.2.  Other Risks of Study P articipation  
Additional risks associated
 with participation  in this study,  include  risks associated with 
phlebotomy  and breach  of confidentiality.  Risks  associated  with phlebotomy  include  
weaknesses,  redness,  pain,  bruising,  bleeding, or infection at the needle site.  Privacy  
protection  procedures  are in place and good clinical practice  guidelines  are followed 
to minimize  the risks  associated with research procedures  and participation.  
 
2.1.3.  Known Potential Benefits 
It is possible that some study subjects receiv ing therapies may experience an improvement 
during the study.  Also, some subjects may not get any benefit from being in this research 
study . The  information learned in this study may benefit future individuals with acute and 
chronic GvHD.  
 
Study number: s20- 00136   Page 9 
Version: 5.1 dtd 2022 Jun 07 
 
9 3. OBJECTIVES AND PURPOSE 
 
STUDY DESIGN:  
3.1. Study hypothesis:  We hypothesize that the administration of cyclophosphamide, abatacept , 
and a short -course of tacrolimus  in the setting of HLA -haploidentical HSCT peripheral blood 
transplantation is effective in the prevention of GvHD and allows prompt immune reconstitution.  
 
3.2. Study overview:   This is a phase Ib-II clinical trial.  Adult patients with hematological 
malignancies undergoing HLA -haploidentical HSCT from first - or second -degree family donor s 
are eligible for the study if they meet the standard criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Patients 
will receive non- myeloablative, reduced -intensity, or myeloablative conditioning regimen at the 
discretion of the transplant physician.  
 
3.3. Objectives 
3.3.1.  P
rimary objectives:  
• Estimate  the incidence of grades II -IV acute GvHD  in patients receiving 
cyclophosphamide, abatacept , and tacrolimus  as GvHD prophylaxis .  
3.3.2.  Secondary objectives:  
• Estimate the incidence of the following: chronic GvHD, primary graft failure, poor 
graft function, and secondary graft failure, TRM, RR, GRFS, OS.  
• Assess immune reconstitution by quantifying CD3+, CD4+, CD8+, and CD19+ in 
comparison to established reference data.  
 
3.4. Study Endpoints  
3.4.1.  Primary study e ndpoints 
Acute GvHD: The first day of acute GvHD of any grade will be used to calculate the 
cumulative incidence for that grade. This endpoint will be evaluated through day +120 
post-transplant .  
3.4.2.  Secondary study e ndpoints  
Chronic GvHD: The first day of chronic GvHD will be used to calculate the cumulative 
incidence of chronic GvHD. This endpoint will be evaluated through day +365 post -
transplant.   
Primary graft failure  is evaluated to day +45  and as defined below .  
Poor graft function  is evaluated to day +30 and as defined below .  
Secondary graft failure  is evaluated following engraftment through day +730 , as defined 
below . 
TRM  are participant deaths not attributable to disease relapse or progression and will be 
evaluated to day +730.  
RR is evaluated to day +730 and is considered the date in which the disease for which 
transplant is performed is evident by methods of disease detection.  
GRFS  is evaluated to day +730 and considers the number of participants that are without 
reported grade III-IV acute GvHD, chronic GvHD requiring systemic therapy and have not 
experienced relapse or death.  
Study number: s20- 00136   Page 10  
Version: 5.1 dtd 2022 Jun 07 
 
10 OS is evaluated to day +730 and considers all participants alive at the end of the study’s 
evaluation period.  
 
3.5. Definitions  
3.5.1.  Engraftment of Neutrophils: A bsolute neutrophil count (ANC) recovery is defined as an 
ANC of ≥ 0.5 x 109/L for three consecutive laboratory values obtained on different days. 
The day used as neutrophil engraftment is the date of the first of three laboratory values.  
3.5.2.  Engraftment of Platelets:  Platelet engraftment is defined as a platelet count ≥ 20 x 109/L 
for 3 consecutive measurements obtained on different days. The patient must not have 
received a platelet infusion for seven consecutive days prior to the first day being 
considered.  The day used as platelet engraftment is the date of the first of three laboratory 
values.   
3.5.3.  Primary graft Failure: Graft failure is defined as failure to achieve neutrophil engraftment 
by day +28 or lack of donor chimerism >  50% by day 45, not due to the underlying 
malignancy .  
3.5.4.  Poor graft function  is defined by at least 2 of the following 3 criteria: H emoglo bin < 8 
g/dL, ANC < 0.5  x 109/L, and platelets < 20 x 109/L. The cytopenia must be unexplained 
(such as by disease relapse) and unresponsive to cytokines  and must last at least 4 
weeks.  
3.5.5.  Secondary graft failure is defined as poor graft function associated with donor chimerism 
< 5%.  
3.5.6.  Acute GvHD : The first day of acute GvHD of any grade will be used to calculate the 
cumulative incidence for that grade (e.g., onset of grade III 70 days post -transplant - time 
to grade III is 70 days). This end point will be evaluated through day +120 post -transplant. 
The diagnosis of a cute GvHD is based on clinical and pathological evaluation by the  
principal investigator in collaboration with the treating physician. The a cute GvHD grading 
system is described in appendix B.  
3.5.7.  Chronic GvHD : The first day of chronic GvHD will be used to calcula te the cumulative 
incidence of c hronic GvHD. The diagnosis of c hronic GvHD is based on clinical and 
pathological evaluation by the principal investigator in collaboration with the treating 
physician. The c hronic GvHD grading system is described in appendix C.  
  
4. STUDY ENROLLMENT AND WITHDRAWAL   
 
ELIGIBILITY:  Patients with hematological malignancies undergoing an allogeneic transplant with a 
conditioning regimen, as described in Appendix B, using an eligible HLA -haploidentical related donor. 
Donors are excluded in case of donor -specific HLA antibodies or positive cross -matching.  Patients 
must meet all of the following inclusion criteria and none of the exclusion criteria. All testing performed 
per BMT SOP: CLNAL002: Related (MRD,  Haplo) Allogeneic RECIPIENT Evaluation and 
Management – Adult and Pediatric and CLNAL003: Related (MRD, Haplo) DONOR Evaluation and 
Management – Adult and Pediatric.  
 
4.1. Inclusion Criteria : 
4.1.1.  Age ≥ 18 years  
Study number: s20- 00136   Page 11  
Version: 5.1 dtd 2022 Jun 07 
 
11 4.1.2.  Karnofsky score ≥ 70%  
4.1.3.  No evidence of progressive bacterial, viral, or fungal infection  
4.1.4.  Creatinine clearance > 50 mL/min/1.72m2 
4.1.5.  Total bilirubin, ALT and AST < 2 x the upper limit of normal (except for diagnosed Gilbert’s 
syndrome)  
4.1.6.  Alkaline phosphatase ≤ 250 IU/L  
4.1.7.  Left Ventricular Ejection Fraction (LVEF) > 45%  
4.1.8.  Adjusted Carbon Monoxide Diffusing Capacity (DLCO) > 60%  
4.1.9.  Negative HIV serology  
4.1.10.  Negative pregnancy test: confirmation per negative serum β -human chorionic 
gonadotropin (β -hCG) for women of childbearing age and potential. 
 
4.2. Exclusion Criteria:  
4.2.1.  Donors are excluded in case of donor -specific HLA antibodies or positive cross -match . 
4.2.2.  Pregnant or nursing females or women of  child bearing age or potential,  who are unwilling 
to completely abstain from heterosexual sex or practice 2 effective methods of contraception from the first dose of conditioning regimen through day +180. A woman of 
reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post -menopausal (stopped 
menstrual periods) for more than 24 months in a row.  
4.2.3.  Male subjects who refuse to practice effective barrier contraception during the entire study treatment period and through a minimum of 90 days after the last dose of study drug, or 
completely abstain from heterosexual intercourse.  This must be done even if they are 
surgically sterilized (i.e., post -vasectomy).  
4.2.4.  Inability to provide informed consent.  
4.2.5.  Patient had m yocardial infarction within 6 months prior to enrollment or has New York 
Heart Association (NYHA) Class III or IV heart failure (see Appendix E), uncontrolled 
angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of 
acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG 
abnormality at screening must be documented by the investigator as not medically relevant.  
4.2.6.  Known allergies to any of the components of the investigational treatment regimen.  
4.2.7.  Serious medical or psychiatric illness likely to interfere with participation in this clinical study.  
4.2.8.  Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.  
4.2.9.  Prisoners  
 
4.3. Inclusion of Women, Minorities and Vulnerable Subjects:  
Both men and women of all races and ethnic groups are eligible for this trial.  
Pregnant women are not included in this study, due to the unknown safety effects to the developing fetus.  Prisoners are not eligible 
 
4.4. Strategies for Recruitment and Retention  
4.4.1.  The inclusion and exclusion criteria in this study should not have a negative effect on 
the enrollment.   
Study number: s20- 00136   Page 12  
Version: 5.1 dtd 2022 Jun 07 
 
12 4.4.2.  Patients will be recruited from physicians participating in this study. Consenting, 
screening, and treatment will take place at the NYU Langone Health PCC under the 
supervision of the principal investigator, Dr. AS Al Homsi.  Prospective subjects will 
receive detailed information regarding this study; its investigational nature, required study procedures, alternative treatments, risks and potential benefits of the study.  They will also 
receive the informed consent document to read.  All questions will be answered by the PI 
or qualified research personnel.  
4.4.3.  
The Principal  Investigator  will: 
1. Obtain signed  and dated informed consent  from the potential subject  before  any 
study  specific  procedures  are performed. Consent may be delegated to a 
trained and qualified licensed professional, as delegated by the principal investigator.
 
2. Deter mine  patient  eligibility;  see Section  4.1 and 4.2 
3. Submit  registration to NYU  Langone  Health PCC  CTO.  
4. Receive registration  confirmation  from the NYU  Langone  Health  PCC  CTO,  
including a unique  study  identification number  assigned  to the patient  that will 
be distributed  to the study  team  upon  registration  of the patient.  Confirmation 
of subject registration must be obtained before any treatment is administered or study procedures are performed.  
4.4.4.  Recruitment and consenting will take place in a private area such as an exam room to protect the patient’s privacy .  The informed consent process and documentation follows 
that established procedures of NYULH Human Subject Research Standard Operating Procedures (HSR 301 Informed Consent Process and Documentation).
  . 
 
4.5. Registration Procedures:  
4.5.1.  General Guidelines:  
Each patient  must  sign and date an informed  consent  form before undergoing 
any study  specific  procedure unless  a procedure  is being  performed as part of the 
patient’s  standard of care.  
Enrollment  in the study  requires  that all inclusion  and exclusion  criteria  have 
been  met. Enrollment  occurs  upon  confirmation  of registration from the NYULH  
PCC CTO.  The following  materials  must  be submitted to the CTO  for subject  
registration:  
1. Complete  signed  and dated  informed  consent  form  
2. Complete  signed  and dated  eligibility  checklist  
3. All supporting documentation  verifying  each eligibility criterion  has been  met 
 Registration  will occur  within  48 hours  of research  coordinator  receipt  of all of the 
above documents.  A
 written  confirmation of enrollment  including  a unique  study  
identification  number  assigned  by the research  coordinator  will be disbursed  to the 
study  team  upon  registration.  
 
Once  eligibility is verified,  a unique patient  study  number  will be issued  within 24 
hours  of receiving  all required registration  material.  The patient  will not be identified  
by name.  This is the point,  at which,  the patient  is considered  accrued  on study.  
Confirmation of subject registration is required  before any treatment is administered or 
Study number: s20- 00136   Page 13  
Version: 5.1 dtd 2022 Jun 07 
 
13 study procedures are performed  (unless a procedure is being performed as part of the 
patient’s standard of care. 
 
 
4.5.2.  Data Reporting to the Center for International Blood and Transplant Research 
(CIBMTR): 
All transplant centers are required to register patients with the Center for International 
Blood and Marrow Transplant Research  (CIBMTR) and complete pre -transplant essential 
data forms, day 100 report forms and follow -up forms. CIBMTR data is covered under 
NYULH IRB: S11 -00861.  
 
4.6. Duration of Study Participation:  
Subjects may remain on study for as long as 2 years, with treatment as detailed in the protocol. Withdrawal due to toxicity, withdrawal of consent, or at the discretion of the investigator may 
occur.  
 
4.7. Total Number of Participants and Sites:  
There will be one  site participating in the study, with a total of 46 participants enrolled, accrued 
over up to 4 years . 
 
4.8. Participants Withdrawal or Termination:  
4.8.1.  Reasons for Withdrawal or Termination : 
A subject has the right to voluntarily discontinue study treatment or withdraw from the study at any time, for any reason, and without repercussion.  The investigator has the right 
to discontinue a patient from study treatment or withdraw a patient from the study at any time. 
 Reasons for subject withdrawal from the study may include, but are not limited to:  
• Subject withdrawal of consent at any time.  
• Disease progression (if applicable)  
• Intolerable toxicity (If applicable)  
• Any medical condition that the investigator determines may jeopardize the patient’s safety if the patient  continues in the study or continues treatment with study drug.  
• The investigator determines it is in the best interest of the patient.  
• Failure of the subject to adhere to protocol procedure requirements  
• Pregnancy (if applicable)  
 
4.8.2.  Handling of Participant Withdrawals or Termination: 
Withdrawal  from the study  can be made in writing  to the Principal  Investigator,  Dr. 
AS Al -Homsi .  
 
4.9. Premature Termination or Suspension of Study:  
This study  may be temporarily  suspended or prematurely  terminated if there is sufficient,  
reasonable  cause.  Written  notification,  documenting  the reason for study  suspension  or 
termination,  will be provided  by the suspending  or terminating  party  to Dr. A Samer Al-
Homsi  and any regulatory  authorities.  If the study  is prematurely  terminated  or suspended, 
Study number: s20- 00136   Page 14  
Version: 5.1 dtd 2022 Jun 07 
 
14 the PI will promptly  inform  the IRB and will provide  the reason(s)  for the termination  or 
suspension.  
Circumstances  that may warrant  termination  or suspension include,  but are not limited  to: 
• Determination of unexpected,  significant, or unacceptable  risk to participants  
• Demonstration of efficacy  that would warrant  stopping  
• Insufficient  compliance  to protocol  requirements  
• Data  that are not sufficiently  complete  or evaluable  
• Determination of futility  
Study  may resume once  concerns  about  safety,  protocol  compliance,  data quality  are 
addressed  and satisfy  the IRB. 
 
4.10.  Stopping Rules   
4.10.1.  Excess TRM  
With 46 patients planned, we will test the hypothesis that the TRM rate is ≤ 8.2%  
versus the alternative hypothesis that the TRM rate is ≥ 20% with one sided α=0.05 
and power of 80%, using an O’Brien Fleming group sequential alpha stopping 
boundary with three (3) interim and one (1) final look as summarized in Table 1 below.  
 
Table 1:  Stopping Boundaries for Excess Transplant Related Mortality (TRM) (1 sided 
α=0.05, power=80%, Ho: TRM≤0.082, Ha: TRM≥0.20) [Calculations from EAST 6.5 Cytel, Inc.].  
 
Interim 
Look Number 
of Patients  Cumulative 
Alpha Spent  Stopping Boundaries:  
Reject TRM≤0.082  
≥Number 
Events  ≥Proportion 
Observed 
1 12 0 5 0.39 
2 23 0.006  6 0.23 
3 35 0.025  7 0.18 
Final  46 0.05 7 0.15 
 
 
4.10.2.  Stopping for excess day -30 grade  4 non -hematologic or any grade 5 regimen-
related toxicity  
With 46 patients planned, we will test the hypothesis that the day-30 grade 4 non-
hematologic  or any grade 5 regimen -related rate is ≤8.2%  versus the alternative 
hypothesis that the day- 30 grade 4 non -hematologic or any grade 5 regimen -
related  rate is ≥ 20% with one sided α=0.05 and power of 80%, using an O’Brien 
Fleming group sequential alpha stopping boundary with three (3) interim and one (1) final look as summarized in Table 2 below.    
 
Table 2 : Stopping Boundaries for Proportion of Patients with Excess Day -30 Grade 4  
non-hematologic or any grade 5 regimen -related Toxicity at Least Possibly Related to 
Study Drugs  at day 30 (1 sided α=0.05, power= 80%, Ho: 30 day proportion ≤0. 082, Ha: 
30 day proportion ≥0. 2) [Calculations from EAST 6.5 Cytel, Inc.]    
Study number: s20- 00136   Page 15  
Version: 5.1 dtd 2022 Jun 07 
 
15  
 
Interim 
Look Number 
of 
Patients  Cumulative 
Alpha Spent  Stopping Boundaries:  
Reject grade 4 non- hematologic 
or any grade 5 regimen- related 
toxicity ≤0.082  
≥Number 
Events  ≥Proportion 
Observed  
1 12 0 5 0.39 
2 23 0.006  6 0.23 
3 35 0.025  7 0.18 
Final  46 0.05 7 0.15 
 
4.10.3 Stopping for excess primary graft failure 
With 46 patients planned, we will test the hypothesis that the primary  graft failure 
rate is ≤ 5% versus the alternative hypothesis that the graft failure rate is ≥ 15% with 
one sided α=0.05 and power of 83%, using an O’Brien Fleming group sequential 
alpha stopping boundary with three (3) interim and one (1) final look as summarized in Table 3 below.
 
 
Table 3 : Stopping Boundaries for Proportion of Patients with Graft Failure Rate  (1 sided 
α=0.05, power= 83%, Ho: 30 day proportion ≤0. 05, Ha: 30 day proportion ≥0. 15) 
[Calculations from EAST 6.5 Cytel, Inc.]  
 
 
Interim 
Look Number 
of Patients  Cumulative 
Alpha Spent  Stopping Boundaries:  
Reject graft failure ≤0.05  
≥Number 
Events  ≥Proportion 
Observed 
1 12 0 4 0.29 
2 23 0.006  4 0.17 
3 35 0.025  5 0.13 
Final  46 0.05 5 0.11 
 
 
5. STUDY AGE NTS 
 
All study agents are FDA -approved for other indications and are commercially available for purchase. 
Cyclophosphamide and abatacept  will be supplied by  NYULH pharmacy.  Tacrolimus is commercially 
available and prescribed to subjects  to pick up from their pharmacy.  
 
5.1. Cytoxan® (cyclophosphamide) – Bristol -Myers Squibb  
5.1.1.  Therapeutic Class: nitrogen mustard alkylating agent  
5.1.2.  Description:   Cytoxan® (cyclophosphamide for injection, USP) is a sterile white powder 
containing cyclophosphamide monohydrate. Cytoxan  Tablets (cyclophosphamide tablets, 
USP) are for oral use and contain 25 mg or 50 mg cyclophosphamide (anhydrous). Inacti ve ingredients in Cytoxan  Tablets are: acacia, FD&C Blue No. 1, D&C Yellow No. 10 
Study number: s20- 00136   Page 16  
Version: 5.1 dtd 2022 Jun 07 
 
16 Aluminum Lake, lactose, magnesium stearate, starch, stearic acid and talc. 
Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen 
mustards. Cyclophosphamide is a white crystalline powder with the molecular formula C
7H15Cl2N2O2P•H 2O and a molecular weight of 279.1. The chemical name for 
cyclophosphamide is 2- [bis (2 -chloroethyl)amino]tetrahydro- 2H-1,3,2 -oxazaphosphorine 
2-oxide monohydrate. Cyclophosphamide is soluble in water, saline, or ethanol and has 
the following structural formula:  
 
5.1.3.  Indications: Treatment of malignant lymphomas, Hodgkin's disease, lymphocytic 
lymphoma, mixed- cell type or histiocytic lymphoma, Burkitt's lymphoma, multiple 
myeloma, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and monocytic leukemia, acute lymphoblastic leukemia in children, mycosis fungoides, neuroblastoma, ovary adenocarcinoma, retinoblastoma, breast carcinoma. 
Treatment of  biopsy proven "minimal change" nephrotic syndrome in children, but not as 
primary therapy.  
5.1.4.  Mechanism of Action: Nitrogen mustard alkylating agent; exerts action by cross linking 
of tumor cell DNA. 
5.1.5.  Pharmacokinetics:  
5.1.5.1.  Absorption: Well absorbed; bioavailabili ty (≥75%).  
5.1.5.2.  Distribution:  Plasma protein binding (≥60% as metabolites ). 
5.1.5.3.  Metabolism:  Liver; active metabolites.  
5.1.5.4.  Elimination:  Urine (5 -25% unchanged); T
1/2=3-12 hrs.  
5.1.6.  How Supplied:   Inj (Lyophilized): 500mg, 1g, 2g; Tab: 25mg, 50mg 
5.1.7.  Administration and Storage:  
5.1.7.1.  Administration:  Oral, IV, IM, intraperitoneal, intrapleural route. Inspect drug 
product visually for particulate matter and discoloration prior to parenteral 
administration.  
5.1.7.2.  Storage:  Vial: Below 25°C (77°F). Tab: Below 25°C (77°F); excursions permitted 
to 30°C (86°F); protect from temperatures above 30°C (86°F).  
 
5.2. Prograf ® (tacrolimus) – Astellas  
5.2.1.  Therapeutic Class: calcineurin- inhibitor  
5.2.2.  Description: Tacrolimus, previously known as FK506, is the active ingredient in Prograf . 
Tacrolimus is a calcineurin- inhibitor immunosuppressant produced by Streptomyces 
tsukubaensis.  
 
The chemical structure of tacrolimus is:  

Study number: s20- 00136   Page 17  
Version: 5.1 dtd 2022 Jun 07 
 
17  
Tacrolimu s has an empirical formula of C 44H69NO12•H2 O and a formula weight of 822.03. 
Tacrolimus appears as white crystals or crystalline powder. It is practically insoluble in 
water, freely soluble in ethanol , and very soluble in methanol and chloroform.  
 
Prograf  is available for oral administration as  capsules (tacrolimus capsules USP ) 
contai ning the equivalent of 0.5 mg, 1 mg or 5 mg of anhydrous tacrolimus USP. Inactive 
ingredients  include croscarmellose sodium NF, hypromellose USP, lactose monohydrat e 
NF, and magnesium stearate NF . The 0.5 mg capsule shell contains ferric oxide NF, 
gelatin NF and titanium dioxide USP , the 1 mg capsule shell contains gelatin NF and 
titanium dioxide USP, and the 5 mg capsule shell contains ferric oxide NF, gelatin NF, and titanium dioxide USP. Prograf  is also available as a sterile solution (tacrolimus injection) 
containing the equivalent of 5 mg anhydrous tacrolimus USP in 1 mL for administration by intravenous infusion only. Each mL contains the following inactive ingredients: dehydrated alcohol USP, 80.0% v/v and polyoxyl 60 hydrogenated castor oil (HCO -60), 200 mg. 
Prograf  injection must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose 
Injection before use. Prograf  Granules is available for oral administration as a suspension 
containing the equivalent of 0.2 mg or 1 mg of anhydrous tacrolimus USP. Inactive 
ingredients include croscarmellose sodium NF,  hypromellose USP, and lactose 
monohydrate NF.  
5.2.3.  Indications: Prograf  is a calcineurin- inhibitor immunosuppressant indicated for the 
prophylax is of organ rejection in adult and pediatric patients receiving allogeneic liver, 
kidney or heart transplants, in combination with other immunosuppressants . 
5.2.4.  Mechanism of Action: Tacrolimus binds to an intracellular protein, FKBP -12. A complex 
of tacrolimus -FKBP- 12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian 
intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is 
inhibited. Such inhibition prevents the dephosphorylation and translocation of var ious 
factors such as the nuclear factor of activated T -cells (NF -AT), and nuclear factor kappa -
light-chain enhancer of activated B -cells (NF -κB). Tacrolimus inhibits the expression 
and/or production of several cytokines that include interleukin (IL) -1 beta, IL -2, IL-3, IL-4, 
IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor -alpha, and granulocyte 
macrophage colony -stimulating factor. Tacrolimus also inhibits IL- 2 receptor expression 
and nitric oxide release, induces apoptosis and production of transforming growth factor 
beta that can lead to immunosuppressive activity. The net result is the inhibition of T-lymphocyte activation and proliferation, as well as T -helper -cell-dependent B -cell 
response (i.e., immunosuppression). 
5.2.5.  Pharmacokinetics:  

Study number: s20- 00136   Page 18  
Version: 5.1 dtd 2022 Jun 07 
 
18 5.2.5.1.  Absorption: Absorption of tacrolimus from the gastrointestinal tract after oral 
administration is incomplete and variable. The absolute bioavailability of tacrolimus 
was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant  patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 
18 ± 5% in healthy volunteers (N = 16). A single dose trial conducted in 32 healthy 
volunteers established the bioequivalence of the 1 mg and 5 mg capsules. Another 
single dose tri al in 32 healthy volunteers established the bioequivalence of the 0.5 
mg and 1 mg capsules. Tacrolimus maximum blood concentrations (C
max) and area 
under the curve (AUC) appeared to increase in a dose- proportional fashion in 18 
fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. In 18 kidney 
transplant patients, tacrolimus trough concentrations from 3 to 30 ng/mL measured 
at 10 -12 hours post -dose (C min) correlated well with the AUC (correlation coefficient 
0.93). In 24 liver transplant patients over a concentration range of 10 to 60 ng/mL, the correlation coefficient was 0.94. In 25 heart transplant patients over a 
concentration range of 2 to 24 ng/mL, the correlation coefficient was 0.89 after an 
oral dose of 0.075 or 0.15 mg/kg/day at steady -state. In a healthy volunteer adult 
study, the systemic exposure to tacrolimus (AUC) for Prograf  Granules was 
approximately 16% higher than that for Prograf  capsules when administered as 
single doses. If pediatric patients are converted between formulations, therapeutic 
drug monitoring must be performed and dose adjustments made to ensure that 
systemic exposure to tacrolimus is maintained.  
Food Effects:  The rate and extent of tacrolimus absorption were greatest under 
fasted conditions. The presence  and composition of food decreased both the rate 
and extent of tacrolimus absorption when administered to 15 healthy volunteers. The effect was most pronounced with a high -fat meal (848 kcal, 46% fat): mean AUC and 
C
max were decreased 37% and 77%, respecti vely; T max was lengthened 5- fold. A 
high-carbohydrate meal (668 kcal, 85% carbohydrate) decreased mean AUC and 
mean C max by 28% and 65%, respectively. In healthy volunteers (N = 16), the time 
of the meal also affected tacrolimus bioavailability. When given immediately 
following the meal, mean C max was reduced 71%, and mean AUC was reduced 39%, 
relative to the fasted condition. When administered 1.5 hours following the meal, mean C
max was reduced 63%, and mean AUC was reduced 39%, relative to the 
fasted condition. In 11 liver transplant patients, Prograf  administered 15 minutes 
after a high fat (400 kcal, 34% fat) breakfast, resulted in decreased AUC (27 ± 18%) and C
max (50 ± 19%), as c ompared to a fasted state. Prograf  capsules should be 
taken consistently every day either with or without food because the presence and composition of food decreases the bioavailability of Prograf . 
5.2.5.2.  Distribution:  The plasma protein binding of tacrolimus is approximately 99% and is 
independent of concentration over a range of 5 -50 ng/mL. Tacrolimus is bound 
mainly to albumin and alpha-1- acid glycoprotein, and has a high level of association 
with erythrocytes. The distribution of tacrolimus between whole blood and plasma 
depends on several factors, such as hematocrit, temperature at the time of plasma 
separation, drug concentration, and plasma protein concentration. In a U.S. trial, the 
ratio of whole blood concentration to plasma concentration averaged 35 (range 12 to 67).  
Study number: s20- 00136   Page 19  
Version: 5.1 dtd 2022 Jun 07 
 
19 5.2.5.3.  Metabolism:  Tacrolimus is extensively metabolized by the mixed- function oxidase 
system, primarily the cytochrome P -450 system (CYP3A). A metabolic pathway 
leading to the formation of 8 possible metabolites has been proposed. Demethylation 
and hydroxylation were identified as the primary mechanisms of biotransformation 
in vitro. The major metabolite identified in incubations with human liver microsomes 
is 13 -demethyl tacrolimus. In in vitro studies, a 31- demethyl metabolite has been 
reported to have the same activity as tacrolimus.  
5.2.5.4.  Elimination:  The mean clearance following IV administration of tacrolimus is 0.040, 
0.083, 0.053, and 0.051 L/hr/kg in healthy volunteers, adult kidney transplant 
patients, adult liver transplant patients, and adult heart transplant patients, 
respectively. In man, less than 1% of the dose administered is excreted unchanged 
in urine.  
5.2.6.  How Supplied:   Intravenous Infusion ( Injection): 5 mg/mL (equivalent of 5 mg of anhydrous 
tacrolimus USP per mL) supplied as a sterile solution in a 1 mL ampule, in boxes of 10 
ampules   Capsule: 0.5 mg, 1 mg and 5 mg. 
5.2.7.  Administration and Storage:  
5.2.7.1.  Administration:  Tacrolimus can cause fetal harm. Prograf  injection must be diluted 
with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a concentration between 0.004 mg/mL and 0.02 mg/mL prior to use. Diluted infusion solution should 
be stored in glass or polyethylene containers and should be discarded after 24 hours. 
The diluted infusion solution should not be stored in a polyvinyl chloride (PVC) container due to decreased stability and the potential for extraction of phthalates. In situations where more dilute solutions are utilized (e.g., pediatric dosing, etc.), PVC -
free tubing should likewise be used to minimize the potential for significant drug adsorption onto the tubing. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Due to the chemical instability of tacrolimus in alkaline media,  
Prograf  injection should not be mixed or co -infused with solutions of pH 9 or greater 
(e.g., ganciclovir or acyclovir). Storage:  Injection: Store between 5°C and 25°C 
(41°F and 77°F). Capsule: Store at 20°C to 25 C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).  
 
5.3. Orencia® ( abatacept ) – Bristol -Myers Squibb  
5.3.1.  Therapeutic Class: selective  T cell co -stimulation modulato r 
5.
3.2. Description:   is  a  soluble  fusion  protein  that  consists  of  the  extracellular  domain  of  
human  cytotoxic  T -lymphocyte
-as
sociated  antigen  4  (CTLA -4)  linked  to  the  modified  
Fc  (hinge,  CH2,  and  CH3  domains)  portion  of  human  immunoglobulin  G1  (IgG1) . 
Abatacept is produced by recombinant DNA technology  in a mammalian cell expression 
system. The apparent molecular weight of abatacept is 92 kilodaltons.  
5.
3.3. Indications: Treatment of adult rheumatoid a rthritis (RA), moderately to severely active 
RA in  adults  and may be used as  monotherapy or concomitantly with DMARDs other than 
TNF antagonist s.  Juvenile idiopathic arthritis , moderately to severely active  polyarticular 
juvenile idiopathic  arthritis  in patients 2 y ears of age and older  (may be used as 
monotherapy or concomitantly with methotrexate). Adult psoriatic arthritis (PsA  active PsA  
in adults. S hould not be given concomitantly with TNF antagonists . 
Study number: s20- 00136   Page 20  
Version: 5.1 dtd 2022 Jun 07 
 
20 5.3.4.  Mechanism of Action: Abatacept,  a  selective  co- stimulation  modulator,  inhibits  T  cell  
(T  lymphocyte)  activation  by  binding to CD80 and CD86, thereby blocking interaction 
with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. Activated T lymphocytes are implicated  in  the  pathogenesis  of  RA  and  PsA  and  are  found  in  the  synovium  of  patients  with  RA and PsA. In vitro, abatacept 
decreases T cell proliferation and inhibits the production of the cytokines TNF alpha 
(TNFα), interferon -γ, and interleukin- 2. In a rat collagen -induced arthritis model, abatacept 
suppresses  inflammation,  decreases  ant i-collagen  antibody  production,  and  reduces  
antigen specific  production  of  interferon -γ. The relationship of these biological response 
markers to the mechanisms  by which ORENCIA exerts its clinical effects is unknown.  
5.3.5.  Pharmacokinetics  
Healthy Adults and Adult RA: Intravenous Administration: The pharmacokinetics of abatacept were studied in healthy adult subjects after a single 10 mg/kg intravenous  infusion  and  in  RA  patients  after  multiple  10  mg/kg  intravenous  infusions  ( table 
below):   
The pharmacokinetics of abatacept in RA patients and healthy  subjects appeared to be 
comparable. In RA patients, after  multiple  intravenous  infusions,  the  pharmacokinetics  
of  abatacept  showed  proportional  increases  of  C
max and  AUC  over  the  dose  range  
of  2  mg/kg to 10 mg/kg.  At 10 mg/kg, serum  concentration  appeared  to  reach  a  steady  state  by  day  60  with  a  mean (range) trough concentration of 24 mcg/mL (1 to 
66 mcg/mL). No systemic accumulation of abatacept occurred upon continued repeated 
treatment with 10 mg/kg at monthly intervals in RA patients. Population  pharmacokinetic  
analyses  in  RA  patients  revealed  that  there  was  a  trend  toward  higher clearance of abatacept with increasing body weight. Age and  gender (when corrected for body weight) 
did not affect clearance. Concomitant methotrexate, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance. No formal studies were conducted 
to examine the effects of either renal or hepatic impairment on the pharmacokinetics of abatacept.  
Adult RA - Subcutaneous Administration: Abatacept exhibited linear pharmacokinetics 
following subcutaneous administration. The mean (range) for C
min and C max at steady state 
observed after 85 days of  treatment was 32.5 mcg/mL (6.6   to   113.8   mcg/mL)   and   
48.1   mcg/mL  (9.8   to   132.4   mcg/mL), respectively. The bioavailability   of   abatacept   
following   subcutaneous administration relative to intravenous administration is 78.6%. 
Mean estimates for systemic clearance (0.28 mL/h/kg)  volum e of distribution (0.11 L/kg),  
and   terminal   half -life   (14.3   days)   were   comparable between subcutaneous and 
intravenous administration. Study  SC- 2 was  conducted  to  determine  the  effect  of  

Study number: s20- 00136   Page 21  
Version: 5.1 dtd 2022 Jun 07 
 
21 monotherapy  use  of  ORENCIA  on immunogenicity  following  subcutaneous  
administr ation  without  an  intravenous load.  When the intravenous loading  dose  was  
not  administered,  a  mean  trough  concentration  of  12.6  mcg/mL was achieved after 2 
weeks of dosing. Consistent with the intravenous data,  population  pharmacokinetic 
analyses for subcutaneous abatacept  in  RA  patients  revealed  that  there  was  a  trend  
toward  higher  clearance  of  abatacept with  increasing  body  weight.  Age  and  gender  
(when  corrected  for  body  weight)  did  not  affect apparent clearance. Concomitant medication, such as methotrexate, corticosteroids, and NSAIDs, did not influence abatacept apparent clearance. Juvenile Idiopathic Arthritis - Intravenous Ad ministration: 
In Study JIA-1 among patients 6 to 17 years of  age, the mean (rang e) steady state serum 
peak and trough concentrations of abatacept were 217 mcg/mL (57 to 700 mcg/mL) and 
11.9 mcg/mL (0.15 to 44.6  mcg/mL).  Population pharmacokinetic analyses of the serum 
concentration data showed t hat clearance  of abatacept increased  with baseline body 
weight.  The estimated mean (range) clearance of abatacept in the juvenile idiopathic 
arthritis patients was 0.4 mL/h/kg (0.20 to 1.12 mL/h/kg). After accountin g for the  effect of 
body weight, the clearance of abatacept was not related to age and gender. Concomitant methotrexate, corticosteroids, and NSAIDs were also shown not to influence abatacept clearance. Juvenile Idiopathic Arthritis - Subcutaneous Administ ration : In Study  JIA-2 
among patients 2  to 17  years of age, steady  state  of   abatacept  was  achieved  by Day  
85  following  the  weekly  body -weight –tiered  subcutaneous  abatacept  dosing.  
Comparable trough  concentrations  across  weight  tiers  and  age  groups  were  achieved  
by  the  body -weight – tiered  subcutaneous  dosing  regimen. The mean (range) trough  
concentration  of  abatacept  at Day 113  was  44.4  mcg/mL  (13.4  to  88.1  mcg/mL),  
46.6  mcg/mL  (22.4  to  97.0  mcg/mL),  and 38.5  mcg/mL  (9.3  to  73.2  mcg/mL)  in  
pediatric  JIA  patients  weighing  10  to  <25  kg,  25  to <50 kg, and ≥50 kg, respectively. Consistent with the  intravenous  data,  population  pharmacokinetic analyses  for  
subcutaneous  abatacept  in  JIA  patients  revealed  that  there  was  a  trend  toward  
higher  clearance  of  abatacept  with  increasing  body  weight. Age  and  gender  (when  
corrected  for  body  weight)  did  not  affect  apparent clearance. Concomitant medication, 
such as methotrexat e, corticosteroids, and NSAIDs, did not influence abatacept apparent 
clearance. Adult Psoriatic Arthritis - Intravenous and Subcutaneous Administr ation: In 
Study, PsA- I, a dose ranging study, IV abatacept was administered at 3 mg/kg, 10 mg/kg 
(weight  range- based dosing: 500 mg for patients weighing less than 60 kg, 750 mg for 
patients weighing 60 to 100 kg, and 1000 mg for patients weighing greater than 100 kg), or two doses of 30 mg/kg followed by  weight   range -based dose of 10  mg/kg . Following 
mont hly IV administration , abatacept showed  linear  PK  over  the  dose  range  of   3  
mg/kg  to  10  mg/kg.  At 10 mg/kg, the steady state of abatacept was reached by Day 57 
and the geometric mean (CV%) trough  concentration  (C
min)  was  24.3  mcg /mL  (40.8 %)  
at  Day  169.  In  Study , PsA-II following weekly  SC  administration  of  abatacept  at  125  
mg,  the  steady state  of  abatacept  was  reached  at   
Day 57 and the geometric mean (CV%) C min was 25.6 mcg/mL (47.7%) at Day 169. 
Consistent  with  the  RA  results,  population  pharmacokinetic  analyses  for  abatacept  in  psoriatic arthritis patients revealed that there was a trend toward higher clearance (L/h) 
of abatacept with increasing  body  weight.  In  addition,  relative  to  the  RA  patients  with  
the  same  body  weight,  abatacept  clearance  in  psoriatic  arthritis  patients  was  
Study number: s20- 00136   Page 22  
Version: 5.1 dtd 2022 Jun 07 
 
22 approximately  8%  lower,  resulting  in  higher abatacept exposures in patients with PsA. 
This slight difference in exposures, however, is not considered to be clinically meaningful.  
5.3.6.  How Supplied:   Intravenous Infusion ( Injection) : 250   mg lyophilized   powder   in   a single 
use vial   for reconstitution and dilution prior to intravenous infusion . Subcutaneous 
Injection: 50 mg/0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL solution in single -dose prefilled 
syringes for subcutaneous use or 125 mg/mL solution in a single- dose  prefilled   ClickJect  
autoinjector for subcutaneous use. 
5.3.7.  Administration and Storage:  
5.3.7.1.  Administration:  ORENCIA for Injection is a  lyophilized powder for intravenous 
infusion. ORENCIA for Injection is  supplied  as  a  sterile,  white,  preservative- free,  
lyophilized  powder  for  reconstitution and  dilution  prior  to  intravenous 
administration.  Following  reconstitution  of  the  lyophilized  powder with  10  mL  of  Sterile  Water  for  Injection,  USP,  the  solution  of  ORENCIA  is  clear,  colorless  to  pale  yellow,  with  a  pH  range  of  7.2  to  7.8.  Each single -use vial of ORENCIA 
for Injection provides 250 mg abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration. ORENCIA Injection is  a sterile, preservative- free, clear to slightly opalescent, colorless to pale-
yellow  solution  with  a  pH  range of  6.8  to  7.4  for  subcutaneous  administration.  
ORENCIA Injection is supplied as a single- dose prefilled syringe or as a single- dose 
Click Ject autoinjector.  
5.3.7.2.  Storage:  ORENCIA lyophilized  powder supplied  in  a  vial  should  be refrigerated  
at  2°C  to  8°C  (36°F  to  46°F). Do not use beyond the expiration date on the vial . 
Protect the vials from light by storing in the original package until time of use. 
ORENCIA solution supplied   in   a   prefilled   syringe or   ClickJect  autoinjector  
should be refrigerated at 2°C to 8°C (36°F to 46°F ). Do not use beyond the expiration 
date on the prefilled syringe or autoinjector. Protect from light by storing in the original 
package until time of use. Do  not allow the prefilled syringe or autoinjector  to freeze. 
 
5.4. Study Agent Accountability Procedures:  
Cyclophosphamide, abatacept, will be purchased per standard of practice from a commercial 
source and compounded according to the package insert by the main hospital pharmacy. If any portion of the study drug is not  administered, the amount infused will be recorded, the principal 
investigator notified and unused medications will be returned to the main hospital pharmacy for disposal.  Tacrolimus is commercially available and is prescribed to subjects  to pick up from their 
pharmacy. During each visit, the dose used of tacrolimus and any adjustments in dosing are reviewed with the subject  and documented in the subject’s EMR.  
 
5.5. Product Complaints:  
A product complaint is a verbal, written, or electronic expression which implies dissatisfaction regarding  the identity, strength, purity, quality, or stability of a drug product. Individuals who 
identify a potential product complaint situation should immediately contact the PI and report the event.  Whenever possible, the associated product should be maintained in accordance with the 
label instructions.  
 
 
6. REQUIRED STUDY ACTIVITIES (APPENDIX A)  
Study number: s20- 00136   Page 23  
Version: 5.1 dtd 2022 Jun 07 
 
23  
6.1. Recipient Pre- Transplant Work -Up and Eligibility for Transplant: The patient will undergo 
pre-transplant work -up per standard of care and in timeframes defined by standard operating 
procedures (SOPs).  This will include but is not limited to: history and physical examination, ABO 
and Rh type, CBC, CMP, PT- INR, PTT, creatinine clearance, high resolution HLA typing 
(including KIR for patients with myeloid malignancies), infectious disease markers (IDMs), β-HCG serum pregnancy test (females of reproductive capability only – refer to exclusion criteria), 
chest x -ray (CXR), E CG, pulmonary function tests (PFT) with DLCO, ECHO to measure left 
ventricular ejection fraction (LVEF), informed consent for transplant, and final medical clearance by their treating physician.
 
6.2. Donor  Work -Up: The donor will also undergo a pre- transplant donor evaluation and eligibility 
per institutional BMT SOPs  (SOP CLNAL003: Related (MRD, Haplo) DONOR Evaluation and 
Management – Adult and Pediatric ). Study procedures will not impact the donor. The attending 
physician will review all donor eligibility prior to the initiation of the conditioning chemotherapy.  
6.3. Pre-Transplant  
6.3.1.  Work up as outlined in 6.1.  
6.3.2.  Daily, from Day -7 through day 0: CBC, CMP, liver function tests (LFTs), and a physical 
exam, including toxicity assessment.  
6.4. Post -Transplant  
6.4.1.  CBC and CMP daily  until neutrophil engraftment, then at least weekly until day +100 (+/ - 
3 days), and at least monthly until day +180 (+/ - 7 days).  
6.4.2.  LFT twice weekly until engraftment, then at least weekly until day +100 (+/ - 3 days), and 
at least monthly until day +180 (+/ - 7 days) . 
6.4.3.  Physical examination including toxicity and GvHD assessments daily until discharge, then weekly until day +100 (+/ - 3 days), and at least monthly until day +180 (+/ - 7 days).  
6.4.4.  From day +180 until day +730: CBC, CMP, LFTs, and a physical exam including toxicity and GvHD assessments will be done at least every three months (+/ - 7 days).  
6.4.5.  Post-chimerism: at engraftment, then at least monthly until day +180, and every 3 months 
until day +730 (+/ - 7 days).  
6.4.6.  Immune reconstitution studies will be drawn on day +30, +100, +180, and +365 (+/ - 7 
days), 10- 20mL of blood for CD3, CD4, CD8 and CD19.  
 
 
7. TREATMENT PLAN 
 
7.1. Conditioning Regimen (Study Schema): Eligible patients will receive one of the following 
conditioning regimens, all of which are standard of care, on an inpatient basis. The choice of the 
conditioning regimen is determined by the treating physician, based on host factors and disease 
nature and status. As described by BMT standard operating policy (procedure) (SOP) CLNT X007: Selection of Conditioning Regimens for Blood and Marrow Transplantation – Adult.
 
 
7.1.1.  Non-myeloablative conditioning : 
7.1.1.1.  Fludarabine 30mg/m2 IV once daily on day -6 , -5, -4, -3, and - 2. 
7.1.1.2.  Cyclophosphamide 14.5mg/kg IV once daily  on day - 6 and -5 
7.1.1.3.  T otal -body irradiation (TBI), 2 grays on day -1.  
Study number: s20- 00136   Page 24  
Version: 5.1 dtd 2022 Jun 07 
 
24 7.1.1.4.  Filgrastim (Neupogen®) will begin on day +7. Filgrastim will be stopped when patients 
achieve an ANC > 1.5 x 109/L on two consecutive days.  
7.1.2.  Reduced- intensity  conditioning:  
7.1.2.1.  Fludarabine 25 mg/m2 IV once daily  on day  - 6, -5, -4, -3 and -2. 
7.1.2.2.  Cyclophosphamide 14.5mg/kg IV once daily  on day - 3 and -2 
7.1.2.3.  B usulfan 130 mg/m2 IV, once daily, on day  -6 and -5  
7.1.2.4.  TBI, 2 grays on day - 1. 
7.1.2.5.  Filgrastim (Neupogen®) will begin on day +7. Filgrastim will be stopped when patients 
achieve an ANC > 1.5 x 109/L on two consecutive days.  
7.1.3.  TBI-based myeloablative conditioning: 
7.1.3.1.  Fludarabine 25 mg/m2 IV once daily on day  -7, -6 and -5  
7.1.3.2.  TBI 150 cGrays bid on day – 4, -3, 2 and -1.  
7.1.3.3.  Filgrastim (Neupogen®) will begin on day +5. Filgrastim will b e stopped when patients 
achieve an ANC > 1.5 x 109/L on two consecutive days.  
7.1.4.  Non TBI-based myeloablative conditioning:  
7.1.4.1.  Fludarabine 25 mg/m2 IV once daily on day  - 6, -5, -4, -3 and -2. 
7.1.4.2.  Cyclophosphamide 14.5mg/kg IV once daily  on day - 3 and -2 
7.1.4.3.  B usulfan 110 mg/m2 IV, once daily, on day  -7, -6 , -5, and -4  
7.1.4.4.  Filgrastim (Neupogen®) will begin on day +5. Filgrastim will be stopped when patients 
achieve an ANC > 1.5 x 109/L on two consecutive days.  
 
7.2. Graft Infusion: At least 2 x 106/kg peripheral blood CD34+ cells (HPC- A) will be infused on day 
0 per institutional protocol. The goal is to infuse 4.9 - 9 x 106/kg CD34+ cells. Stem cells are 
collected by apheresis after donor mobilization with 10 µg/kg of filgrastim (G -CSF or Neupogen®) 
per the National Marrow Donor Program and institutional program practice.  
 
7.3. GvHD P rophylaxis: All patients will investigational GvHD prophylaxis based on a combination 
of PTCy , abatacept and tacrolimus. No other prophylactic treatment will be given.  
7.3.1.  Cyclophosphamide 50 mg/kg IV over 1 hour on day +3 and +4 with concomitant 
hydration. The hydration will be NS with or without 20 mEq/L KCl at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is complete. Furosemide is also given on an as needed basis to maintain fluid balance.  
7.3.2.  Abatacept 10mg/kg IV over 30 minutes on day +5, +14, and +28.   
7.3.3.  Tacrolimus 0.02 mg/kg IV by continuous infusion starting on day +5. The drug can be 
changed to oral route when the patient has adequate oral intake. The target trough level 
is 5-12 ng/mL. Treatment is continued until day +60 (+/ -3) and then tapered over a period 
of 4 weeks in the absence of GvHD.  
 
7.4. Drug Preparation:  The drugs will be prepared under the supervision of a pharmacist, or 
appropriately qualified and trained personnel. All doses will be based on adjusted body surface area if actual body weight is >125% the ideal body weight.  
 
7.5. S
upportive care : Steroids will not  be allowed after graft infusion. All supportive care including 
anti-emetics, anti -seizure, sinusoidal obstruction syndrome (SOS) prophylaxis, transfusion 
support, and infection prophylaxis will be administered per established routine institutional SOPs.  
All deviations must be documented by the principal investigator prior to occurrence.   
Study number: s20- 00136   Page 25  
Version: 5.1 dtd 2022 Jun 07 
 
25  
7.6. Management of acute and chronic GvHD:  Patients who develop acute or chronic GvHD will 
be managed by the treating physician according to his or her standard practice and as defined 
by BMT SOP CL NAL005: Definition, Prevention, Diagnosis, Grading, and Management of Graft -
versus -Host-Disease (GvHD) – Adults.  
 
7.7. Patients will remain on study for follow -up and data collection.  
 
7.8. Ancillary Therapy:  Patients will continue to receive any other therapy that the treating physician 
feels necessary according to the routine program practices.  Management of shared toxicities 
and adverse events associated with cyclophosphamide, abatacept and tacrolimus such as 
nausea, vomiting, diarrhea, etc. will be routinely managed according to the routine practices.  
 
7.9. Dose adjustments: No dose adjustments are allowed for cyclophosphamide.  Abatacept must 
be discontinued in case of severe l ife threatening allergic reaction and in case of uncontrolled 
infection. Abatacept therapy can be resumed once the infection is controlled.  Tacrolimus dose 
will be adjusted to maintain drug level as specified above in 7.3. 3. The  subject  will be withdrawn 
from the study if, at the discretion of the treating physician:  
1. The subject  cannot receive the planned treatment with cyclophosphamide.  
2. The subject  cannot receive at least 1 dose of abatacept.   
3. The subject  cannot receive at least 4 weeks of tacrolimus.  
 
8. ASSESSMENT OF SAFETY  
 
8.1. Specification of Safety Parameters  
Adverse Events (AE) and Serious Adverse Events (SAE) are unexpected toxicities that occur in the transplant setting (i.e. hematologic, gastrointestinal toxicities are expected). The Common Terminology Criteria for Adverse Events, Version 5.0, will be used for assessing the severi ty of 
adverse events.  
8.1.1.  The following will be reported and monitored:  
• Grade 3  or higher,  non-hematologic toxicity directly related to study drugs (such 
as peripheral neuropathy).  
• Grade 2 or higher hepatic bilirubin.  
 
8.1.2.  Time  Period and Frequency for Event Assessment and Follow -up 
The investigator or site staff will be responsible for detecting, documenting and reporting events that meet the definition of an adverse event (AE) or serious adverse event (SAE). AEs and SAEs will be followed from the start of conditioning regimen to day +60 or until 
treatm ent-related adverse events, occurring before day +60 resolve or stabilize.  
 
8.2. Adverse Events (AE) : 
8.2.1.  Definition  of Adverse Events (AE)  
An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study, which is unexpected. Intercurrent 
illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic 
procedures are considered to be adverse events if the abnormality:  
Study number: s20- 00136   Page 26  
Version: 5.1 dtd 2022 Jun 07 
 
26 • results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by the investigator to be of clinical significance  
 
8.2.2.  Reporting an Adverse Event:  All adverse events, whether observed by the investigator 
or reported by the patient, must be recorded with details.  Information to be collected 
includes event description, time of onset, clinician’s assessment of severity, relationship to study pr oduct (assessed only by those with the training and authority to make a 
diagnosis), duration of episode, intensity of episode, action taken with respect to the test drug, time of stabilization and resolution of the event and patient outcome. The investigat or 
must evaluate each adverse event for its relationship to the test drug and for its seriousness. The clinical course of each event should be followed until resolution, 
stabilization, or until it has been determined that the study treatment or participation is not 
the cause.  All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate report forms. All unexpected AEs occurring while on study must be documented appropriately regardless of relationship.  
 
8.3. Serious Adverse Events (SAE) : 
8.3.1.  Definition of S erious Adverse Events (SAE)  
Events are classified as serious or non- serious.  A serious adverse event  is any AE that 
is: 
• fatal 
• life-threatening 
• requires or prolongs hospital stay  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize the subject, and may require 
intervention to prevent one of the other serious outcomes noted above. For example, drug 
overdose or abuse, a seizure that did not result in in- patient hospitalization, or intensive 
treatment of bronchospasm in an emergency department would typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as 
non-serious adverse events . 
 
8.3.2.  Reporting a Serious Adverse Event:  The Principal Investigator (PI), Dr. A. Samer Al-
Homsi, (who may also sometimes be referred to as the sponsor -investigator), is conducting 
the study and acting as the sponsor. Therefore, the ethical and legal obligations of the principal investigator include both those of a sponsor and those of an investigator.  
 
Study number: s20- 00136   Page 27  
Version: 5.1 dtd 2022 Jun 07 
 
27 All SAEs, regardless of expectedness or relationship with any study drug, must be reported 
to the sponsor -investigator, as soon as possible, but no later than 24 hours of the 
investigator’s observation or awareness of the event.  
The occurrence of an AE or SAE may come to the attention of study personnel during study 
visits and interviews of a study participant presenting for medical care, or upon review by 
a study monitor.  
 SAEs that are still ongoing at the end of the study period must be followed up to determine the final outcome.  Any serious adverse event that occurs after the study period and is considered to be possibly related to the study treatment or study participation should be 
recorded and reported immediately. 
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s 
condition deteriorates at any time during the study, it will be recorded as an AE. 
Unanticipated Problems (UP) will be recorded in the data collection sys tem throughout the 
study.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent 
require documentation of onset and duration of each episode.  
 
At each contact with the subject, the investigator must seek information on adverse events by specific questioning and, as appropriate, by examination.  Information on all adverse 
events should be recorded immediately in the source document, and also in the appropriate 
adverse event module of the case report form (CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results should recorded in the source document, though should be grouped under one diagnosis. At each st udy visit, the investigator will 
inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for 
outcome information until resolution or stabilization.    
 
All unresolved adverse events should be followed by the investigator until the events are resolved, the subject is lost to follow -up, or the adverse event is otherwise explained.  At 
the last scheduled visit, the investigator should instruct each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.    
   
Events should be reported using the NYU CTO Medical Events Form. 
 
Adverse events that do not fit the above immediately reportable criteria must still be reported to the IRB at each annual review, either in a summary or tabular format.  
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion 
of an UP report form. It is the site investigator’s responsibility to report UPs to their IRB and  
to the overall principal investigator. The UP report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB 
project number;  
Study number: s20- 00136   Page 28  
Version: 5.1 dtd 2022 Jun 07 
 
28 • A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.  
 To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline: 
• UPs that are SAEs will be reported to the IRB within 10 working days  and to the 
DSMC /Principal Investigator/Medical Monitor  for all fatal or life threatening adverse 
events within 24 hours of the investigator becoming aware of the event. 
• Any other UP will be reported to the IRB and to the DCC within 10 working days  of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by an 
institution’s written reporting procedures), the supporting agency head (or designee), 
and OHRP within 10 working days of the IR’s receipt of the report of the problem from the investigator.  
SAE reporting will  begin  in conjunction with the date of treatment  administration.  Any 
SAEs that the investigator  believes  may have been caused  by a protocol  procedure  
must  be reported immediately  to the principal  investigator,  assigned medical 
monitor, and a notification  email  sent to NYUPCCsafetyreports@nyulangone.org  
and recorded  on the case  report  form.  
 
All fatal or life-threatening adverse  events  must  be immediately  reported  to the 
Principal  Investigator,  via appropriate  reporting  mechanism  and the NYU Langone  
Health  IRB by telephone  or e-mail.  Within  24 hours  of the event,  the Serious  Adverse 
Event  Form  must  be emailed  to the principal investigator, assigned medical monitor, 
and NYUPCCsafetyreports@nyulangone.org whether  fu ll  information regarding  the 
event  is known  or not.  
 
Additional  follow -up by the investigator  will be required  if complete  information is not 
known.  De-identified  source  documentation  of all examinations,  diagnostic  
procedures,  etc. which  were  completed  with respect  to the event  should  be 
included with the SAE form.  For laboratory  results,  include  the laboratory  normal  
ranges.  
 The Serious  Adverse Event  Form  must  also be emailed  to the
 principal  investigator , 
assigned medical monitor  and DSMC, and NYUPCCsafetyreports@nyulangone.org     
within 24 -hours of  the event  whether  full information  regarding the event  is known or 
not. Additional  follow -up by the investigator  will be required  if complete  information  is 
not known.  
 
Current  contact  information shall  be maintained  at the site within  the regulatory  binder.  
 
All SAEs will be evaluated  by the DSMC . The investigator  is responsible  for reporting  
all SAEs to the appropriate IRB and DSMC . 
Study number: s20- 00136   Page 29  
Version: 5.1 dtd 2022 Jun 07 
 
29  
8.4. Overdose: 
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE.  
 
8.5. Other Safety Considerations: 
Any significant worsening noted during interim or final physical examinations, electrocardiograms, X -rays, and any other potential safety assessments, whether or not these 
procedures are required by the protocol, should also be recorded as a non- serious or serious 
AE, as appropriate, and reported accordingly.  
 
8.6. Definition of Unanticipated Problems (UP) : 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets a
 ll of the following criteria:  
• Unexpected in nature, severity, or frequency  (i.e. not described in study -related 
documents such as the IRB -approved protocol or consent form, the investigators 
brochure, etc.) 
• Related or possibly related to participation in the research  (i.e. possibly related 
means there is a reasonable possibility that the incident experience, or outcome may have been caused by the procedures involved in the research)  
• Suggests that the research places subjects or others at greater risk of harm  
(including physical, psychological, economic, or social harm). 
 
8.
7. Classification of an Adverse Event : 
8.7.1.  Severity of Event  
As described, AEs will be graded by criteria established by CTCAE, version 5.0. For AEs  
not able to be defined by this grading system, the following guidelines will be used to 
describe severity.  
• Mild:  Events require minimal or no treatment and do not interfere with the participant’s 
daily activities.  
• Moderate:  Events result in a low level of  inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with 
functioning.  
• Severe: Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life -threatening 
or incapacitating.  
8.7.2.  Relationship to Study Agent  
For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on t emporal relationship and  clinical judgment. The  
degree of certainty about causality will be graded using the categories below.  
• Definitely Related: There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to drug administration and cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug (dechallenge) should be clinically plausible. The event must 
Study number: s20- 00136   Page 30  
Version: 5.1 dtd 2022 Jun 07 
 
30 be pharmacologically or phenomenologically definitive, with use of a satisfactory 
rechallenge procedure if necessary. 
• Probably Related: There is evidence to suggest a causal relationship, and the 
influence of other factors is unlikely. The clinical  event, including an abnormal 
laboratory test result, occurs within a reasonable time after administration of the drug, is unlikely to be attributed to concurrent disease or other drugs or chemicals, and 
follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
• Possibly Related: There is some evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the trial medication) . 
However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related,” as appropriate.  
• Unlikely to be related: A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to drug administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the trial medication) and in which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical condition, other 
concomitant treatments).  
• Not Related: The AE is completely independent of study drug administration, or 
evidence exists that the event is definitely related to another etiology. There must be 
an alternative, definitive etiology documented by the clinician.  
 
8.8. Non-serious Adverse Event Collection Reporting:  
The collection of non- serious AE information should begin from the start of conditioning regimen. 
All non -serious adverse events (not only those deemed to be treatment -related) should be 
collected continuously during the treatment period and to a minimum of day +60 post -transplant.  
 Non-serious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious. Follow- up is also required for non- serious AEs that cause interruption or 
discontinuation of study drug and for those present at the end of study treatment as appropriate.  
 
8.9. Expectedness: 
The Principal investigator and/or sub- investigator(s) will be responsible for determining whether 
an AE is expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the 
study agent.  
 
8.10.  Reporting of Pregnancy:  
Procedures for  Reporting Drug Exposure during Pregnancy and Birth Events: If a woman 
becomes pregnant or suspects that she is pregnant while participating in this study, she must inform the investigator immediately and permanently discontinue study drug(s). The pregnancy 
must be followed for the final pregnancy outcome (i.e., delivery, still birth, miscarriage) and PI will request this information from the investigator. If a female partner of a male patient becomes pregnant during the male patient’s participation in this study, this must be reported to PI 
Study number: s20- 00136   Page 31  
Version: 5.1 dtd 2022 Jun 07 
 
31 immediately.  Every effort should be made to follow the pregnancy for the final pregnancy 
outcome.  
 
The pregnancy  must  be reported  immediately  to the principal  investigator,  and the DSMC  
by emailing:  NYUPCCsafetyreports@nyulangone.org .  P regnancy  in itself is not regarded  
as an adverse event  unless  there is a suspicion  that the investigational  product  may 
have  interfered with the effectiveness  of a contraceptive  medication.  
 
8.
11. Reporting Procedures - Notifying the IRB:  
Federal regulations  require  timely  reporting  by investigators  to their local  IRB of unanticipated 
problems  posing  risks  to subjects  or others.  The following  describes  the NYULH  IRB 
reporting  requirements,  though Investigators  at participating sites  are responsible for 
meeting  the specific  requirements  of their IRB of record.  
 Report  promptly,  but no later than 10 working days:
 
 
Researchers  are required  to submit  reports  of the following  problems  promptly  but no later 
than 10 working  days  from the time the investigator  becomes  aware of the event:  
• Unanticipated problems  including  adverse  events  that are unexpected  and related and 
harmful.  
– Unexpected : An event  is “unexpected”  when its specificity  and severity are not 
accurately  reflected  in the protocol -related documents,  such  as the IRB-
approved research  protocol,  any applicable  investigator  brochure,  and the 
current  IRB-approved informed  consent  document  and other  relevant  sources  
of information,  such as product  labeling  and package inserts.  
– Related  to the research  procedures : An event  is related to the research 
procedures  if in the opinion of the principal  investigator,  the event  was more  
likely  than not to be caused  by the research  procedures.  
– Harmful : either  caused  harm  to subjects  or others,  or placed  them  at increased risk 
 
Other Reportable  events:  
 
The following  events  also require prompt  reporting to the IRB, though  no later than 10  
working days:  
• Complaint  of a research  subject  when the complaint  indicates  unexpected  risks  or 
the complaint  cannot  be resolved  by the research  team.  
• Protocol  deviations  or violations (includes  intentional and accidental/unintentional  
deviations  from the IRB approved protocol)  for any of the following  situations:  
– one or more  participants  were  placed at increased  risk of harm  
– the event  has the potential  to occur  again  
– the deviation was necessary  to protect  a subject  from immediate  harm  
• Breach of confidentiality  
• Incarceration of a participant  when the research  was not previously  approved  under  
Subpart  C and the investigator  believes  it is in the best interest  of the subject  to 
remain  on the study.  
• New Information  indicating  a change  to the risks  or potential  benefits  of the 
Study number: s20- 00136   Page 32  
Version: 5.1 dtd 2022 Jun 07 
 
32 research,  in terms  of severity  or frequency.  (e.g. analysis  indicates  lower -than-
expected response  rate or a more  severe  or frequent  side effect;  Other  research 
finds  arm of study  has no therapeutic  value;  FDA labeling  change or withdrawal  
from market)  
 
8.12.  Reporting  Process:  
The reportable  events  noted above  will be reported  to the IRB using  the form:  “Reportable  
Event  Form” or as a written report  of the event  (including  a description  of the event  with 
information regarding  its fulfillment  of the above  criteria,  follow -up and resolution  and need  
for revision  to consent  form and/or  other  study  documentation).  Copies  of each  report  and 
documentation of IRB notification  and receipt  will be kept in the Clinical  Investigator’s  study  
file. 
 
 
 
8.13.  Other Reportable  events:  
Exceptions to  the study protocol  
Exceptions to  the protocol  must  obtain investigator’s  IRB approval  before they are initiated.  
Any protocol deviations  initiated  without  the investigator’s  IRB approval  that may affect  the 
scientific  soundness  of the study,  or affect  the rights,  safety,  or welfare  of study  subjects,  
must  be reported  to the investigator’s  IRB as soon  as a possible,  but no later  than  10 
working  days  of the protocol  deviation.  
 
8.
14. Study Halting Rule s 
 
8.14.1.  Removal of Subjects from Study  
8.14.1.1.  The investigator will make every reasonable effort to keep each subject  in the study 
until all planned treatments and assessments have been performed. Unplanned 
discontinuation may occur for any of the following reasons:  
• Subject  develops allergy to either study drug.  
• Treating physician feels that continuation in study is not appropriate.  Such a determination may be made if the subject  experiences adverse events related 
to the study protocol of ≥ grade 3 other than hematologic or infection -related 
toxicity that the physician or PI determines the study is no longer in the 
subject’s best interest.  See also 7.9.  
• Subject  withdraws informed consent.  
• Subject  is not meeting the follow up requirements  
8.14.1.2.  If subjects  fail to complete the study treatment, alternative GVHD prophylaxis will 
be instituted immediately at the discretion of the treating physician.  
8.14.1.3.  The PI can decide to replace subjects  withdrawn from the study at his discretion. All 
subjects  who receive cyclophosphamide, at least 1 dose of abatacept and 1 month 
of tacrolimus, will be evaluated (see 7.9) .  The study will enroll subjects  for a total 
of 46 evaluable subjects , expected to be accrued over up to four years . 
8.14.1.4.  Premature Closure of Study: This study may be prematurely terminated, if in the opinion of the sponsor -investigator, there is sufficient reasonable cause. Written 
notification documenting the reason for study termination will be provided by the 
Study number: s20- 00136   Page 33  
Version: 5.1 dtd 2022 Jun 07 
 
33 terminating party. Circumstances that m ay warrant termination include but are not 
limited to: 
• Determination of unexpected, significant, or unacceptable risk to subjects , 
• Failure to enter subjects  at an acceptable rate,  
• Failure Insufficient adherence to protocol requirements,  
• Insufficient complete or evaluable data,  
• Plans to modify, suspend, or discontinue the development of the drug.  
 
8.15.  Safety Oversight : 
All Internal  SAEs  reported by the CTO,  occurring to patients  on clinical  trials  that are not 
monitored by any other  institution  or agency,  are reported  to the principal investigator, the medical 
monitor and the DSMC via  email:  NYUPCCsafetyreports@nyulangone.org and r eviewed  
within  48 hours  by the medical monitor.  Based  on the review,  one of three  determinations  
will be made:  
 
• SAE report  is considered  to be adequate.  
• Queries  for clarification  to PI regarding treatment  attribution  and/or  resolution  of SAE 
or completeness  of other  information.   
• The committee  may request  a cumulative  review  of all SAEs on the study  to date.  
Request  for full DSMC  committee  review of protocol  at the next scheduled meeting.  
 
The DSMC  Coordinator  will record  the committee’s  decision  and incorporate  it into the study  
summary  for the next scheduled  study  review.  
 
9. CLINICAL MONITORING 
 
Clinical site monitoring is conducted to ensure that the rights and well -being of human subjects are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with 
applicable regulatory requirement(s). 
 
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This safety monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -monitoring 
plan detailed below.  Adverse events are evaluated regularly by the princ ipal investigator in 
conjugation with the research team, the DSMC is notified of adverse events via email initially, and then reviewed at the next DSMC monthly meeting.  The Data Safety and Monitoring Committee (DSMC) will review the study quarterly .  Medi cal monitoring will include a regular assessment of the 
number and type of serious adverse events.  
 
9.1. Data Monitoring Committee  
This investigator -initiated study will be monitored by the Data Safety Monitoring Committee 
(DSMC) of the New York University (NYU) Perlmutter Cancer Center (PCC). The DSMC operates based on the 2017 National Cancer Institute approved Charter.  It is an existing and 
multidisciplinary committee (consisting of clinical investigators/oncologists, biostatisticians, 
Study number: s20- 00136   Page 34  
Version: 5.1 dtd 2022 Jun 07 
 
34 nurses, and research administration staff knowledgeable of research methodology and design 
and in proper conduct of clinical trials) that is responsible for monitoring safety, conduct and 
compliance in accordance with protocol data monitoring plans for interventional clinical trials conducted in the NYULH Perlmutter Cancer Center that are not monitored by another institution or agency. The DSMC report s to the Director of the NYULH PCC.   
 Per the NYU PCC Institutional Data Safety and Monitoring Plan, this Phase II trial will be monitored by DSMC quarterly  (from the date the first patient is enrolled), at protocol -specified 
interim time points, and at the completion of the study prior to study closure.  
This review  
includes  accrual  data,  subject  demographics  and adverse events.  Principal  Investigators  
are required to attend the review  of their studies.  Additional  reviews  can be scheduled  
based  on SAE reports,  investigator  identified  issues,  external  information,  etc.  The 
DSMC will review safety data every 3 months. DSMC summary reports are available to facilitate the review and monitoring of this study.    These reports include the following:  patient  
listings and summary reports that describe study enrollment and accrual, eligibility, demographic characteristics, dose modifications, adverse experiences, subject’s death and additional external published data if applicable to the study.  Cumulative toxi cities, SAEs, 
and AEs are reviewed, to identify possible adverse events with elevated frequency that is unexpected.  Once a recommendation is  made , if further action is required, the 
Investigator’s must respond within the timeframe specified by the DSMC.
 
 
10. STATISTICAL CONSIDERATIONS  
 
10.1.  Sample S ize:  
The primary outcome variable for this study is the incidence of grades II -IV acute GvHD.   We 
assume that the rate of grade II -IV acute GvHD , with the standard of care is 50%  [21-23], as 
reported in the literature and 30% in the experimental group. Based on a 2- stage optimal Simon 
design, we can detect a reduction in the grade II –IV acute GvHD incidence to 30% for high -
dose post -transplant cyclophosphamide, a batacept and tacrolimus wit h alpha = 0.05 and power 
of 82% at the conclusion of the 2- stage design with 46 patients . The trial would stop for futility 
at the end of the first stage if 9 or more patients have grade II -IV acute GVHD , of the 22 patients 
enrolled. Otherwise, the trial will continue to the second stage with the total 46 patients enrolled. 
If the total number of patients with grade II -IV acute GVHD is 19 or greater at the end of stage 
II, the regimen will not be considered for further study. The rate of grade II -IV acute GVHD will 
be estimated at the end of the trial with exact 95% Clopper Pearson confidence intervals. If the observed rate is 30%, this exact confidence inter val with 46 patients , the corresponding 
confidence interval will be 17. 4% to 45 .3%. Calculations from PASS 2019, NCSS, J. Hintze, 
Kaysville, Ut.  
 
Additional monitoring rules are provided above for excess transplant related mortality and for 
excess drug related toxicity or graft failure. Each of these two rules incorporate 3 interim safety 
evaluations and one final safety evaluation at the completion of the trial.  
 
The study will be stopped for safety at any one of these interim safety evaluations should the 
criteria for either endpoint be reached without adjustment for the two parallel analyses.  
Study number: s20- 00136   Page 35  
Version: 5.1 dtd 2022 Jun 07 
 
35 All participants that receive post -transplant cyclophosphamide and at least 1 dose of abatacept 
and 1 month of tacrolimus will be included in interim  safety evaluations.  
 
10.2.  Statistical Analysis:  
Baseline Descriptive Statistics: Patient characteristics will be summarized using descriptive 
statistics. For qualitative characteristics (such as gender, co -morbid conditions, donor source, 
CMV status amongst others) proportions and frequency distributions will be provided. For 
quantitative characteristics including hematologic parameters, summary and graphical displays will be provided  
 
10.3.  Analysis of the Primary Efficacy Endpoint(s):  
10.3.1.  Grades II -IV Acute GvHD : The first day of grades II -IV acute GvHD will be recorded for 
that grade. This end point will be evaluated through day +120 post -transplant. The diagnosis 
of acute GvHD is based on clinical and pathological evaluation by the principal investigator 
in collaboration with the treating physician. The acute GvHD grading system is described in 
appendix B. All participants that received a transplant and received cyclophosphamide, and at least 1 dose of abatacept and a month of tacrolimus will be included in the analysis. Cumulative incidence curves will be provided along with 95% confidence intervals for the 120 day cumulative incidence. 
 
10.4.  A nalysis of the Secondary Endpoint(s):   
All analyses of secondary endpoints will be based on cumulative incidence curves of Kaplan Meier curves to estimate the rates of occurrence as defined for each endpoint.  
10.4.1.  Chronic GvHD: The first day of chronic GvHD will be used to calculate the cumulative 
incidence of chronic GvHD. This end point will be evaluated through day +365 post -
trans plant.  The diagnosis of chronic GvHD is based on clinical and pathological evaluation 
by the principal investigator in collaboration with the treating physician. The chronic GvHD system is described in appendix C. The analysis will be based on the maximum grade of 
chronic GvHD. All participants that completed transplant  and any prophylactic treatment 
will be included in the  analysis. An additional analysis will be carried out for all pati ents 
that received a transplant and completed prophylactic treatment with evalu ation from date 
of completion of prophylactic treatment.  Cumulative incidence curves will be provided 
along with 95% confidence intervals for the day 365 cumulative incidence. Additional 
descriptive analyses will be provided for any GvHD TRM  
10.4.2.  Primary graft failure  is evaluated to day +45 and incidence of graft failure will be 
calculated from date of transplant to failure for all patients who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all 
participants that completed treatment.   
10.4.3.  Poor graft function  is evaluated to day +30 incidence of poor graft function will be 
calculated, from date of transplant to failure for all  patients who receive a transplant and 
any prophylactic treatment and from date of completion of prophylactic treatment for all 
participants that completed treatment.   
10.4.4.  Secondary graft failure  is evaluated after engraftment is achieved will be calculated f rom 
date of engraftment for all patients with engraftment.   
Study number: s20- 00136   Page 36  
Version: 5.1 dtd 2022 Jun 07 
 
36 10.4.5.  TRM  will be analyzed based on participants that who received a transplant with any 
prophylactic treatment and for all patients who received a transplant and completed 
prophylactic treatment.  
10.4.6.  RR is evaluated to day +730 and will be analyzed for all patients who received a transplant 
and for all transplanted patients that completed treatment.  
10.4.7.  GRFS  is evaluated to day +730 and considers as successes participants that are without 
reported GvHD III -IV acute GvHD, chronic GvHD requiring systemic therapy and have not 
experienced relapse or death after transplant.  
10.4.8.  OS is evaluated to day +730 and considers all participants who received a transplant and 
for all transplanted patients who completed prophylactic treatment as described above.  
 
10.5.  Missing D ata:  
Distribution of patients and disease characteristics will be summarized for patients with missing data regarding key endpoints or who are non -compliant.  Comparisons will be made to patients 
who complete the study to evaluate bias.  
 
10.6.  Safety Analyses:   
All adverse events (expected and unexpected) will be tracked and graded per CTCAE, version 5.0 over time.  In addition, the attributed relationship to study drug will be summarized. All 
adverse events will be reviewed by the primary investigator, in conjunction with the sub-
investigators to determine safety.  
 
11. SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA AND 
DOCUMENTS  
 
Source data is all information, original records of clinical findings, observations, or other ac tivities 
in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are 
contained in source documents.  Examples of these original documents, and data records include: 
hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and records kept at the 
pharmacy, at the laboratories, and at medico- technical departments involved in the clinical trial. It 
is acceptable to use CRFs as source documents. If this is the case, it should be stated in this section what data will be collected on CRFs and what data will be collected from other sources. 
 
TrialMaster,  an electronic  database  capture  system  will be created  to record  the data for 
this trial. Research  coordinators  will input  clinical  trial data into the database.  This database 
is password  protected  and only the PI, assigned study  team  members,  and CTO  staff 
will have  access  to the database.  DataCore,  a core resource  of the institution,  will provide 
the primary  data collection  instrument  for the study.  All data requested  in the system  must  
be reported.  All missing  data must  be explained. The quality  assurance  (QA) specialists  will 
provide extensive monitoring including real -time review of all eCRFs to ensure completeness and 
compliance with the protocol.  A first subject audit is to be conducted within four weeks of enrollment.  
 
Study number: s20- 00136   Page 37  
Version: 5.1 dtd 2022 Jun 07 
 
37 Source documentation  should  be consistent  with data entered into any electronic  medical  
record  or TrialMaster.  Relevant  source  documentation to be reviewed by the QA specialists  
throughout  the study  includes but are not limited to:  
1. Baseline  measures  to assess  pre-transplant  status  
2. Treatment records  
3. Adverse events  
 
12. QUALITY ASSURANCE AND QUALITY CONTRO L 
 
This study will be monitored according to the monitoring plan detailed below.  The Investigator will 
also ensure that the monitor or other compliance or quality assurance reviewer is given access to all the above noted study -related documents and study related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.) as necessary. A risk -based, data -driven monitoring approach will be used to verify 
data for this trial, which will also include a centralized review of data for quality, trends, consistency 
and general safety review.  A quality assurance specialist will regularly review the progress of the 
trial, study data and site processes.  At each visit, the monitor will review various aspects of the trial including, but not limited to:  screening and enrollment logs; compliance with the protocol and study manual and with the principles of Good Clinical Practice; completion of case report forms; source 
data verification; study drug accountability and storage; fa cilities and staff.  
 
During scheduled monitoring visits, the investigator and the investigational site staff must be available to discuss the progress of the trial, make necessary corrections to case report form entries, respond to data clarification requests and respond to any other trial- related inquiries of the 
monitor. Any queries identified through this review will be managed within the systems established for query resolution and tracking. Inquiries related to study conduct, which require further information or action will be discussed within the study team for appropriate and documented 
escalation plans. It is expected that response to data clarification requests and other trial -related 
inquiries will occur throughout the course of the study through regular communication with the site monitor, the Sponsor or representatives, and review/entry of data into the electronic study database.  
At any time during the course of  the study,  representatives  of the FDA and/or  local  regulatory  
agencies  may review the conduct  or results  of the study  at the investigational  site. The 
investigator  must  promptly  inform  NYU  PCC CTO  of any audit  requests  by health authorities,  
and will provide  the results  of any such  audits  and with copies  of any regulatory  documents  
related  to such  audits.  
 In accordance  with HIPAA  and associated  privacy  regulations,  a patient’s  authorization to use 
personal
 identifiable  health information may be required from each  patient  before  
commencement  of research  activities.  This authorization document  must  clearly  specify  what  
parties  will have  access  to a patient’s  personal  health  information,  for what  purpose and for 
what  duration.  
 
At the NYU Perlmutter  Cancer  Center,  all investigator -initiated  protocols  are subject  to a 
standardized  data and safety  monitoring,  which  includes  scientific  peer review,  IRB review and 
DSMC  review as well as internal  auditing.  
 
Study number: s20- 00136   Page 38  
Version: 5.1 dtd 2022 Jun 07 
 
38 The review  of AEs and trial conduct  for this trial occurs  at several  levels:  
 
(1) Principal  Investigator: Adverse events  are evaluated monthly  by the principal  
investigator  in conjunction  with the research  nurses,  data manager  and 
research team.  
 
(2) DSMC, quarterly  
 
(3) Institutional  Review  Board  (IRB):  An annual  report  to the IRB is submitted  by 
the trial PI for continuation  of the protocol.  It includes  a summary  of all AEs,  
total enrollment  with demographics,  protocol  violations,  and current  status  of 
subjects  as well as available  research  data.  
 
In addition,  the quality  assurance  unit will conduct  monitoring of this trial every 4- 6 weeks; this  
includes real -time review of all eCRFs to ensure completeness and to verify adherence to the 
protocol; the completeness, accuracy and consistency of the data; and adherence to ICH Good 
Clinical Practice guidelines.  Additionally, a first subject audit is to be conducted within four weeks of enrollment.  
 
13. ADMINISTRATIVE REQUIREMENTS  
 
13.1.  Good Clinical Practice:   
The study will be conducted in accordance with the International Conference on Harmonization 
(ICH) for Good Clinical Practice (GCP) and the appropriate regulatory requirement(s).85 The 
investigator will be thoroughly familiar with the appropriate use of the study drugs as described 
in the protocol and Investigator’s Brochures. Essential clinical documents will be maintained to demonstrate the validity of the study and the integrity of the data collected.  Master files should be established at the beginning of the study, maintained for the duration of the study, and 
retained according to the appropriate regulations.
 
 
13.1.1.  Ethical Considerations:  The study will be conducted in accordance with ethical principles 
founded in the Declaration of Helsinki. The IRB will review all appropriate study documentation in order to safeguard the rights, safety and well -being of the patients. The 
study will only be conducted at sites where IRB approval has been obtained. The protocol, 
Investigator’s Brochure, informed consent, advertisements (if applicable), written information given to the patients, safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB by the investigator . 
 
13.1.2.  Protocol Compliance: The investigator will conduct the study in compliance with the 
protocol, and given approval by the IRB, and the appropriate regulatory authorit ies. Any 
departures from the protocol must be fully documented in the source documents.  
 
13.2.  Patient Information and Informed Consent:   
After the study has been fully explained, written informed consent will be obtained from the patient.  The method of obtaining and documenting the informed consent and the contents of 
the consent will comply with ICH- GCP and all applicable regulatory requirement(s).  
Informed 
Study number: s20- 00136   Page 39  
Version: 5.1 dtd 2022 Jun 07 
 
39 consent  is a process  that is initiated  prior to the individual’s  agreeing  to participate  in the 
study  and continues  throughout  the individual’s  study  participation.  Extensive  discussion of 
risks  and possible  benefits  of participation will be provided  to the participants  and their 
families.  Consent  forms  will be IRB-approved  and the participant  will be asked  to read and 
review  the document.  The investigator  will explain  the research  study  to the participant  and 
answer  any questions  that may arise.  All participants  will receive  a verbal  explanation  in 
terms  suited  to their comprehension  of the purposes,  procedures,  and potential  risks  of the 
study  and of their rights  as research participants.  Participants  will have the opportunity  to 
carefully  review  the written  consent form and ask questions  prior to signing.  The participants  
should have  the opportunity  to discuss the study  with their surrogates  or think  about  it prior 
to agreeing to participate.  The participant  will sign the informed  consent  document  prior to 
any procedures  being  done specifically for the study.  The participants  may withdraw 
consent  at any time throughout  the course  of the trial. A copy  of the signed  informed  
consent  document  will be given to the participants  for their records.  The rights  and welfare  
of the participants  will be pr otected by emphasizing  to them  that the quality  of their medical  
care will not be adversely  affected  if they decline to participate  in this study.  
 
A copy  of the signed  informed  consent  document  will be stored in the subject’s  research 
record.  The consent  process,  including  the name  of the individual  obtaining  consent,  will be 
thoroughly  documented in the subject’s  research  record.  Any alteration  to the standard 
consent process  (e.g. use of a translator,  consent  from a legally  authorized  representative,  
consent  document  presented orally,  etc.) and the justification  for such  alteration  will likewise  
be documented.  
 
The consenting process  and documentation will follow  Standard  Operating Procedures  
(Obtaining  Informed Consent  for Clinical Trials)  of the NYULH  PCC CTO.  
 
13.2.1.  Informed Consent:  Consent  will be obtained  only by a participating investigator  
who has completed requisite  training  for human subject  research  and has been  
instructed  by the Principal  Investigator  about  the research  study  and consent  
process.  Investigators  will review  the informed consent  form with patients  and 
address  any questions  or concerns  prior to obtaining  written  informed  consent  for 
participation and HIPAA  authorization.  
 
For non-English  speaking patients,  institutional translation services  will be utilized.  
All procedures  for consenting  non-English  speaking patients  will be in accordance 
with NYU  Langone  Health  PCC CTO  guidelines  and policies.  
 
For patients  who cannot  read;  a witness,  not related  to the research  study  will be 
present.  The consent  will be read to the patient.  The patient  will also be allowed  
to ask any questions  the patient may have.  The investigator  will ask the patient  
questions  to ensure that the patient understands  the study.  If the investigator  
determines  the subject  understands  the study,  the patient  will mark  an X where the 
patient  name  would  go and the witness  will sign the consent  form.  
 
Study number: s20- 00136   Page 40  
Version: 5.1 dtd 2022 Jun 07 
 
40 13.2.2.  Documentation of Consent:  The Principal Investigator  or IRB approved sub-
investigator  will be responsible  for documentation  in the medical  record  that consent 
has been obtained from all participants.  A signed  copy  of the consent  form will be 
given  to each participant.  Original  consent  forms  will be stored  in the subject’s  medical  
chart.  
 
13.2.3.  Posting of Clinical Trial Consent : The informed consent form will be posted on the 
Federal website after the clinical trial is closed to recruitment and no later than 60 days 
after the last study visit by any subject, as required by the protocol.  Per Institutional 
guidelines, SOP#: HSR -601, instructs the principal investigator on registration and results 
reporting on cl inicaltrials.gov.  
 13.2.4.  Participant and Data Confidentiality:  In order to maintain participant privacy, all 
information obtained in connection with this study which identifies the participant will 
remain confidential in accordance with state and federal law.  
 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the 
following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorizat ion for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, 
attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 Participant confidentiality is strictly held in trust by the participating investigators and their 
staff. This confidentiality is extended to cover testing of biological samples and genetic 
tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence.  
 
Representatives of the IRB may inspect all documents and records required to be 
maintained by the investigator, including but not limited to, medical records (office, clinic,  
or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study.  At the end of the study, all records will continue to be kept 
in a secure location for as long a period as dictated by local IRB and Institutional regulations.  
Study number: s20- 00136   Page 41  
Version: 5.1 dtd 2022 Jun 07 
 
41  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at NYU Langone Health. This will not include the participant’s contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data 
entry and study management systems used by clinical sites and by NYU Langone Health 
research staff will be secured and password protected. At the end of the study, all study databases will be de- identified and archived at the NYU Langone Health.  
 
14. DATA  HANDLING  AND  RECORD KEEPING  
 14.1.  Data  Collection  and Management  Responsibilities:
 
Data  collection is the responsibility  of the clinical trial staff at the site under  the 
supervision of the site PI. The investigator  is responsible  for ensuring  the accuracy,  
completeness,  legibility,  and timeliness  of the data reported.  
 
All source  documents  should  be completed  in a neat,  legible manner  to ensure  accurate 
interpretation of data.  Black  ink is required  to ensure  clarity  of reproduced copies.  When 
making  changes  or corrections,  cross  out the original  entry  with a single  line, and initial  
and date the change.  DO NOT  ERASE,  OVERWRITE,  OR USE  CORRECTION  FLUID  
OR TAPE  ON THE ORIGINAL.  
 
Data  reported  in the eCRF  derived from source  documents  should be consistent  with 
the source  documents  or the discrepancies  should  be explained  and captured in a 
progress  note and maintained  in the participant’s  official  electronic  study  record.  
 
Clinical  data (including  AEs,  concomitant  medications, and expected  adverse reactions  
data)  and clinical  laboratory  data will be entered into TrialMaster,  a 21 CFR  Part 11-
compliant  data capture  system  provided by DataCore. The data system  includes  password 
protection  and internal  quality  checks  to identify  data that appear  inconsistent,  
incomplete,  or inaccurate.  Clinical  data will be entered  directly  from the source  documents.  
 
I
nvestigational product records are maintained by the NYU Langone Health Pharmacy. 
Cyclophosphamide and abatacept are provided by the NYU Langone  Health pharmacy, 
however, Tacrolimus is commercially available and is prescribed to subjects  to pick up from 
their pharmacy. All prescription records are maintained in subject ’s EMR . 
 
14.2.  Study Records Retention : 
The sponsor -investigator will maintain all study records according to ICH -GCP and applicable 
regulatory requirement(s).  
 
14.3.  Protocol Deviations : 
A protocol  deviation  is any noncompliance  with the clinical  trial protocol,  GCP, or Manual  
of Procedures  (MOP)  requirements.  The noncompliance  may be either  on the part of the 
Study number: s20- 00136   Page 42  
Version: 5.1 dtd 2022 Jun 07 
 
42 participant,  the investigator,  or the study  site staff.  As a result  of deviations,  corrective  
actions  are to be developed by the site and implemented  promptly.  
 
These practices  are consistent  with ICH E6: 
• 4.5 Compliance  with Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
• 5.1 Quality  Assurance and Quality  Control,  section  5.1.1  
• 5.20 Noncompliance,  sections  5.20.1,  and 5.20.2.  
 
Protocol  deviations  must  be reported  to the local  IRB per their guidelines.  The site PI and 
study  staff is responsible  for knowing  and adhering  to their IRB requirements.   All protocol  
deviations  must  be addressed in study  source  documents  and reported  to IRB Program  
Official at the time of annual continuing review.  If a protocol deviation is determined to be reportable new information, the IRB will be notified immediately.
 
 
14.4.  Publication and Data Sharing Policy : 
This study  will comply  with the NIH Public  Access Policy,  which ensures  that the public 
has access  to the published  results  of NIH funded research.  It requires  scientists  to 
submit  final peer-reviewed  journal  manuscripts  that arise  from NIH funds  to the digital  
archive  PubMed Central  upon acceptance  for publication.  
 
The International  Committee of Medical  Journal  Editors  (ICMJE)  member  journals  have  
adopted a clinical  trials  registration policy  as a condition for publication.  The ICMJE  
defines  a clinical  trial as any research  project  that prospectively  assigns  human 
subjects  to intervention or concurrent  comparison or control  groups  to study  the cause -
and-effect  relationship  between  a medical  intervention and a health outcome.  Medical 
interventions  include  drugs,  surgical  procedures,  devices,  behavioral  treatments, 
process -of-care changes,  and the like. Health  outcomes  include  any biomedical  or 
health- related measures  obtained  in patients  or participants,  including pharmacokinetic  
measures  and adverse events.  The ICMJE  policy,  and the Section  801 of the Food and 
Drug  Administration  Amendments  Act of 2007,  requires  that all clinical  trials  be 
registered  in a public  trials  registry  such  as ClinicalTrials.gov,  which  is sponsored by the 
National  Library  of Medicine.  Other  biomedical  journals  are considering  adopting similar  
policies.  For interventional  clinical  trials  performed  under  NIH IC grants  and cooperative  
agreements,  it is the grantee’s  responsibility  to register  the trial in an acceptable  
registry,  so the research  results  may be considered  for publication  in ICMJE  member  
journals.  The ICMJE  does  not review  specific studies  to determine whether  registration 
is necessary;  instead,  the committee  recommends  that r esearchers  who have 
questions  about  the need  to register  err on the side of registration  or consult  the editorial  
office  of the journal  in which they wish to publish.  
 S
tudy results  may be published, and participants may access the results of this study via 
clinicaltrails.gov or any published media.  However, no results will be sent directly to subjects. The study will be available on clinicaltrials.gov.
 
 
15. STUDY FINANCE S 
Study number: s20- 00136   Page 43  
Version: 5.1 dtd 2022 Jun 07 
 
43  
15.1.  Funding Sour ce:  
All study elements are standard of care and will be billed to third parties. The data management 
cost will be covered by the Disease Management Group (DMG).  
 
15.2.  Costs to the Participant :  
All aspects of care, including conditioning regimen and GvHD prevention is considered standard of care and will be billed to the insurance company or participant.
 
 
15.3.  Participant Reimbursements or Payments:  
No subject will receive payments or stipends for participation in this research study.  
 
16. CONFLICT OF INTEREST POLICY  
 
Any investigator  who has a conflict  of interest  with this study  (patent  ownership,  royalties,  or 
financial  gain greater  than the minimum allowable by their institution,  etc.) must  have  the 
conflict  reviewed  by a properly  constituted  Conflict  of Interest  Committee with a Committee -
sanctioned conflict  management  plan prior to participation  in this study.  All NYULH  
investigators  will follow  the applicable  University  conflict  of interest  policies.  
 
  
Study number: s20- 00136   Page 44  
Version: 5.1 dtd 2022 Jun 07 
 
44 17. REFERENCES  
 
1. Appelbaum FR. Hematopoietic cell transplantation at 50. N Engl J Med  2007;  357:1472- 1475.  
2. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand. 
Hematology Am Soc Hematol Educ Program 2012; 230 -236. 
3. Gladstone DE, Zachary A, Fuchs EJ, et al. Desensitization for mismatched hematopoietic stem cell transplantation (HSCT). Blood 2011; 1955 (abstract).  
4. Fuchs ET, et al. Related haploidentical donors are a better choice than matched unrelated donors: point. Blood Advances 2017; 6: 397-400.  
5. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA -mismatched related bone 
marrow or unrelated double umbilical cord blood grafts. Blood 2011; 2:382- 288.  
6. Bertaina A; Merli P; Rutella S; Pagliara D; Bernardo ME; Masetti R, et al. HLA -haploidentical 
stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant 
disorders. Blood 2014; 124: 822-826. 
7. Balashov D; Shcherbina A; Maschan M; Trakhtman P; Skvortsova Y; Shelikhova L, et al. Single-
Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with 
TCRalphabeta and CD19 Depletion in Children with Primary Immunodeficiency Syndromes.  Biol 
Blood Marrow  Transplant 2015; 21:1955- 1962 . 
8. Bertaina A; Zecca M; Buldini B; Sacchi N; Algeri M; Saglio F, et al. Unrelated donor vs HLA -
haploidentical alpha/beta T -cell- and B -cell-depleted HSCT in children with acute leuke mia. 
Blood 2018; 132:2594-2 607. 
9. Luznik L, Bolaños -Meade J, Zahurak M, et al. High- dose cyclophosphamide as single- agent, 
short -course prophylaxis of graft -versus -host disease. Blood 2010; 115: 3224- 3230.  
10. Fuchs EJ, Selective allodepletion: have we finally found the holly grail? Biol Blood Marrow Transplant 2013; 19:1413- 1414.  
11. Kankary GK, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi -institutional 
study of post -transplant cyclophosphamide as single- agent graft -versus -host disease 
prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. Journal Clin Oncol  2014; 32:3497 -3505.  
12. Kanate AS; Mussetti A; Kharfan- Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A, et al. Reduced -
intensity transplantation for lymphomas using haploidentical related donors vs HLA -matched 
unrelated donors. Blood 2016; 127:938- 947. 
13. McCurdy SR; Kanakry JA; Showel MM; Tsai HL; Bolanos -Meade J; Rosner GL, et al. Risk -
stratified outcomes of nonmyeloablative HLA -haploidentical BMT with high- dose 
postt ransplantation cyclophosphamide. Blood 2015; 125:3024- 3031 . 
14. Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN, et al. Reduced- intensity 
transplantation for lymphomas using haploidentical related donors versus HLA -matched sibling 
donors: a center for international blood and marrow transplant research analysis. J Clin Oncol 2016; 34:3141- 3149 . 
15. Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK, et al. T- cell replete HLA -
haploidentical hematopoietic transplantation for hematologic malignancies  using post -
transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donot transplantation. J Clin Oncol 2013; 31:130- 1316.   
Study number: s20- 00136   Page 45  
Version: 5.1 dtd 2022 Jun 07 
 
45 16. Raiola AM; Dominietto A; di Garzia C; Lamparelli T; Gualandi F; Ibatici A, et al. Unmanipulated 
haploidentical transplants comapred to with other alternative donors and matched sibling grafts. 
Biol Blood Marrow transplant 2014; 20: 1573 -1579. 
17. Herrero -Beaumont G, Martinez Calatrava MJ, Castaneda S. Abatacept mechanism  of actions: 
concordance with its clinical profile. Rheumatol Clin 2012; 2:78 -83. 
18. Watkins BK, Qayed M, Bratrude B, et al. T cell blockade with CTLA4 -Ig (Abatacept) for acute 
GvHD prevention in HLA matched and mismatched unrelated donor transplantation: res ults of 
the first phase 2 trial. Biol Blood Marrow Transplant 2019; 65 (abstract).  
19. Patel A, Yong J. Elimination of acute GvHD with three doses of abatacpet prophylaxis combined with post -transplant cyclophosphamide after myeloablative treosulfan- based conditioning in the 
HLA identical sibling and unrelated (10 -12/12) peripheral blood stem cell donor setting: improved 
safety and efficacy compared to alemtuzumab prophylaxis. Blood 2019; 4540 (abstract).  
20. Kasamon YL, Fuchs EJ, Zahurak M, et al. Short ened- duration aftet non -myeloablative, HLA-
haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2018; 5:1022- 1028.  
21. Solomon SR, Sizemore CA, Sanacore M et al. Total body irradiation- based myeloablative 
haploidentical stem cell transplantation is  a safe and effective alternative to unrelated donor 
transplantation in patients without matched sibling. Biol Blood Marrow Transplant 2015; 21:1299 -
1307.  
22. Baker M, Wang H, Rowley SD, et al. Comaprative outcomes after haploidentical or unrelated 
donor bone marrow or blood stem cell transplantation in adult patients with hematological 
malignancies. Biol Blood Marrow Transplant 2016; 22:2047- 2055.  
23. Kanate AS, Mussetti A, Kharfan_Dabaja MA, et al. Reduced -intensity transplantation for 
lymphoma using haploidentical related donors vs HLA -matched donors. Blood 2016; 127: 938-
947. 
 
18. APPENDICES  
18.1.  Appendix A: Required Study Activities  
18.2.  Appendix B: Acute Graft -Versus -Host Disease Assessment (aGVHD)  
18.3.  Appendix C: Chronic Graft -Versus -Host Disease Assessment (cGVHD)  
18.4.  Appendix D: New York Heart Association (NYHA) Classification of Cardiac Disease  
 
 
 
    
  
Study number: s20- 00136   Page 46  
Version: 5.1 dtd 2022 Jun 07 
 
46 18.1 APPENDIX  A: REQUIRED STUDY ACTIVITIES  
 
1Pre-transplant: per standard of care 
2Pre-tranplant: collect CBC, CMP, liver function tests, and physical exam, including toxicity assessments  
3 Cyclophosphamide administered Day +3 and Day +4 
4 Tacrolimus initiated on Day +5  
5 Abatacept given on Day +5, +14, +28  
6 Post-chimerism: at neutrophil engraftment, then at least monthly (+/- 7 days) until day +180, and every 3 
months  (+/- 7 days)  until day +730.  
7Blood samples for immune reconstitution will be collected on day +30, +100, +180, and +365 (+/ - 7 days)  after 
transplant . 
 
 
    
18.2
 APPENDIX  B: ACUTE GRAFT VERSUS HOST DISEASE ASSESSMENT (aG vHD)  
 
Activity  Pre-Study
1 Day -7 
to Day 
-1
2 Day 0  Day 
+3 Day +4  
   Day 
+5  
 
  Day 
+14  
 
  Day 
+28 Daily 
until 
Neutrophil Engr
aftme
nt   
Daily until disch
arge Twic
e a 
week until Engr
aftme
nt Week
ly 
until Day +100 
(+/- 3 
days)  Mont
hly 
until Day +180 
(+/- 7 
days)  Every 3 
months until Day+730 (2 
years) (+/ -
7days)  
Study team  
procedures                
Consent  X              
Medical History  X              
Physical Exam  X X X      X X  X X X 
KPS X           X X X 
Height  X              
Weight  X X             
Vital Signs  X X       X X  X X X 
Cychlophophamide
3    X X          
Tacrolius4      X         
Abatacept5      X X X       
Toxicity 
Assessment   X X      X X  X X X 
GVHD Assessment          X X  X X X 
Chimerism6         X    X X 
Immune 
Reconstitution 
Samples7         
      
Medication Review  X X X X X X X X X X X X X X 
Laboratory 
Assessments                
CBC,CMP  X X X      X   X X X 
LFTs   X X        X X X X 
Study number: s20- 00136   Page 47  
Version: 5.1 dtd 2022 Jun 07 
 
47  
Overall Grade  aGvHD  
 Skin  Liver  Gut 
0 none  0 0 0 
1 mild  1-2 0 0 
2 moderate  1-3 1 1 
3 severe  2-3 2-3 2-3 
4 life threatening  2-4 2-4 2-4 
 
  Clinical staging of aGVHD  
Stage  Skin  Liver (bilirubin)  Gastro -intestinal tract  
0 No rash  < 2.0 mg/dL  No persistent nausea, vomiting or 
anorexia. Diarrhea ≤ 500 ml/day  
1 Maculopapular rash < 25% of body 
surface  2.0-3.0 mg/dL  Persistent nausea, vomiting or anorexia . 
Diarrhea 501- 1000 ml/day with biopsy 
proof . 
2 Maculopapular rash 25 -50% body 
surface  3.1 – 6.0 mg/dL  Diarrhea 1001 -1500 ml/day  
3 Generalized erythroderma  6.1 – 15 mg/d  Diarrhea > 1500 ml/day  
4 Generalized erythro -derma with blister 
or bullous formation and 
desquamation  >15 mg/dL  Severe abdominal pain without or with  
Study number: s20- 00136   Page 48  
Version: 5.1 dtd 2022 Jun 07 
 
48 18.3  APPENDIX  C: CHRONIC GRAFT VERSUS HOST DISEASE ASSESSMENT (cGVHD)  
The involved organs are scored as follows:  
KPS: Karnofsky’s performance status. BSA: body surface area. GI: gastrointestinal. LFT: liver function tests. AP: 
alkaline phosphatase. SOB: shortness of breath. LFS: lung function score (FEV1 and DLCO are converted into 
numeric scores and added to each other to get the LFS: > 80% = 1, 70- 79% = 2, 60- 69% = 3, 50- 59% = 4, 40- 49% 
5, < 40% 6). ADL: activities of daily life.  
 Score  
Organ  0 1 2 3 
KPS 100%  80-90% 60-70% < 60%  
Skin  No symptoms  < 18% BSA  19-50% BSA or sclerotic features 
but able to pinch > 50% BSA or sclerotic changes and 
unable to pinch or with impaired 
mobility  
Mouth  No symptoms  Not limiting oral intake significantly  Limiting oral intake partially  Limiting oral intake severely  
Eyes  No symptoms  Dryness, requiring eye -drops ≤ 
3/day or asymptomatic  
keratoconjunctivitis sicca (KCS)  Dryness, requiring eye -drops > 
3/day without visual impairment  Unable to work because of ocular 
symptoms or vision loss  
GI tract  No symptoms  < 5% weight loss  5-15% weight loss  > 15% weight loss requiring calorie 
supplements or esophageal dilation  
Liver  Normal LFT  Elevated bilirubin, AP, AST, or ALT 
< 2 X normal  Elevated bilirubin, AP, AST, or ALT  
2-5 X normal  Elevated bilirubin, AP, AST, or ALT  5 X 
normal  
Lungs  No symptoms, FEV1 
> 80% or LFS  2  SOB after 1 flight of steps FEV1 60 -
70% or LFS 3 -6 SOB walking flat, FEV1 40 -59% or 
LFS 6-9 SOB at rest or requiring O 2, FEV1 ≤ 
39% or LFS 10 -12 
Joints and 
fascia  No symptoms  Mild decrease in range of motion not 
affection ADL  Moderate decrease in range of 
motion with moderate impairment of 
ADL Significant de -crease in range of 
motion with significant impairment of 
ADL 
Genital 
tract  No symptoms  Symptoms and with mild signs on 
exam and no effect on coitus  Symptoms and with moderate signs 
on exam with discomfort on coitus  Symptoms and with advanced signs on 
exam such as strictures or ulcerations 
with severe pain on coitus  
 
The following is checked and scored  (0 -3) as applicable:  
Esophageal stricture or web  
Pleural effusions  
Pericardial effusion  
Ascites 
Platelets < 100 109/L  
Eosinophils > 0.5 109/L 
Peripheral neuropathy  
Polymyositis  
Myasthenia gravis  
Coronary artery disease 
Cardiac conduction defects  
Cardiomyopathy  
Based on the organ scoring the severity of cGVHD is defined as follows:  
Mild cGVHD: involvement of 1- 2 organs with maximum scores of 1 in all affected organs or sites.  
Moderate cGVHD: 1. involvement of 1- 2 organ involvement with a maximum score of 2 in any affected organ or site 
(except for lungs). 2. involvement of 3 or more organs with maximum score of 1 in all affected organs or sites.  
Severe cGVHD: a lung score of 2 or a score 3 in any organ or site.  
 
  
Study number: s20- 00136   Page 49  
Version: 5.1 dtd 2022 Jun 07 
 
49 18.4  APPENDIX D : NEW YORK HEART ASSOCIATION CLASSIFICATION OF CARDIAC DISEASE  
The following table presents the NYHA classification of cardiac disease.  
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting limitations of 
physical activity.  Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or an ginal pain.  No objective evidence of 
cardiovascular disease.  
II Patients with cardiac disease resulting in slight limitation of physical 
activity.  They are comfortable at rest.  Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.  Objective evidence of minimal 
cardiovascular disease.  
III Patients with cardiac disease resulting in marked limitation of physical 
activity.  They are comfortable at rest.  Less than ordinary activity 
causes fatigue, palpitation, dyspnea, or  anginal pain.  Objective evidence of moderately 
severe cardiovascular disease.  
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort.  Symptoms of heart failure or the anginal syndrome may be present even at rest.  If any physical activity is undertaken, discomfort is increased.  Objective evidence of severe 
cardiovascular disease.  
Source:  The Criteria Committee of New York Heart Association.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.  9th Ed. Boston, MA:  Little, Brown & Co; 1994:253- 256. 
 
 